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Abstract
Optimization of Orthogonal Translation Systems Enhances Access to the Human
Phosphoproteome
Jack Michael Moen
2021
Protein phosphorylation is a ubiquitous post-translational modification that governs
signaling cascades and protein-protein interactions. Orthogonal translation systems, in
which an orthogonal aminoacyl-tRNA synthetase and tRNA pair have been repurposed for
insertion of a non-standard amino acid, have been developed for co-translational insertion
of phospho-amino acids. Here, we systematically developed variants of phosphoserine and
phosphothreonine orthogonal translation systems to minimize cellular toxicity and
maximize translational fidelity. We characterized novel tRNA constructs to enhance
cellular fitness and change decoding functionality. Multiple genetic background strains
were developed to enhance the incorporation of phospho-amino acids into recombinant
proteins. Utilizing large-scale DNA synthesis, we produced serine, threonine, and tyrosine
libraries representative of the entire known human phosphoproteome. By pairing our
libraries with a bimolecular fluorescence complementation assay, we characterized novel
phosphorylation-dependent

protein-protein

interactions

for

phosphoserine,

phosphothreonine, and phosphotyrosine. Genetically encoded phosphothreonine enabled
the discovery of a new activation mechanism for the protein kinase CHK2 and proteomewide surveys of its target substrates. Finally, we developed Hi-P+ to couple kinase
substrate discovery with phosphorylation-dependent protein-protein interactions. This

work enables kinase-specific, proteome-wide surveys of multi-level phosphorylationdependent interactions with phosphosite resolution.

Optimization of Orthogonal Translation Systems Enhances Access to the Human
Phosphoproteome

A Dissertation
Presented to the Faculty of the Graduate School
of
Yale University
in Candidacy for the Degree of
Doctor of Philosophy

by
Jack Michael Moen
Dissertation Director: Jesse Rinehart, Ph.D.
December 2021

© 2021 by Jack Michael Moen
All rights reserved.

Dedication
This document is dedicated to my wife, Alexandra.
I would not be here today without your constant love and support in my life.
Nothing is impossible with you at my side.

ii

Acknowledgments
For the science: The only reason I have come so far is because of the great mentors
I have had in my life. I would like to thank Dr. Lisa Julian for teaching me that science
requires hard work and discipline to succeed. I would also like to thank Dr. Jerry Schaack
for teaching me that science is a creative endeavor, first and foremost. Dr. Ed Lakatta for
cultivating scientific curiosity and mentoring me through the complexities of the world
within. Dr. Jesse Rinehart for pushing me to produce the highest quality work. Without his
mentorship, this document would not be possible. More than once, his enthusiasm for
science helped me to reframe negative results into positive progress forward. Most
importantly, I would like to thank Dr. Kyle Mohler for working with me every day down
in the trenches. Without his mentorship, I would have never been pushed to do the type of
science I now know I am capable of doing. I would also like to thank my thesis committee,
Dr. Benjamin Turk, Dr. Farren Isaacs, and Dr. Susumu Tomita, for their guidance and help
during this project. I would also like to thank everyone that has come through both Jesse
Rinehart’s and Farren Isaac’s lab during my time at Yale. These interactions enriched my
life and scientific knowledge.
For everything else: First and foremost, I would like to thank my wife Alexandra
for her love and support during my graduate career. There were highs and lows over the
last few years, but she was always my constant. For my father, whose intellectual curiosity
and love of puzzles still resonates within me today. For my mother and all the times, she
stayed up with me as a child to help me learn to read and write. For my brothers, we had
many struggles throughout life, but I know I am a better person for having you both there
to challenge me. Lastly, I would like to thank my extended family for their love and
support. I know my grandparents would have been proud to see how far I have come.
iii

Table of Contents
Dedication .......................................................................................................................... ii
Acknowledgements .......................................................................................................... iii
Table of Contents ............................................................................................................. iv
List of Figures & Tables ................................................................................................ viii
Chapter 1: Introduction ................................................................................................... 1
Protein translation ........................................................................................................... 1
Suppressor tRNAs ........................................................................................................... 8
Incorporation of non-standard amino acids ................................................................... 11
The advent of orthogonal translation systems ............................................................... 12
Recoded Organisms....................................................................................................... 16
Chapter 2: Optimizing the incorporation of phospho-amino acids in E. coli ........... 19
Refining orthogonal translation component expression ................................................ 19
Establishing a robust pThrOTS ................................................................................. 19
Expanding the stability of pSerOTS components ...................................................... 24
Exploration of tRNA usage in orthogonal translation systems ..................................... 28
tRNA copy number stability in pThrOTS design ....................................................... 28
pSerOTS tRNA variations .......................................................................................... 32
Inducing tRNA transcription with self-splicing RNA elements ................................. 34
Changes in tRNApSer recognition elements enable Ala suppression .......................... 37
iv

Expanding the phosphoamino-acid genetic code to UGA codons ............................ 39
Genetic modifications to E. coli enhance phospho-protein production ........................ 42
Recombinant pThr protein production is enhanced in phosphatase deletion strains 42
The optimized pSerOTSc is minimally toxic in C321 ................................................ 47
Incorporation of pTyr is limited by intracellular pTyr pools .................................... 51
Chapter 3: Applications of the incorporation of phospho-amino acids ..................... 55
Systems biology approaches to understanding protein-protein interactions ................. 55
Mapping the phospho-interactome of 14-3-3β .......................................................... 55
Evolutionarily conserved PBDs interact with human phosphosites.......................... 59
The pTyr SH2 PBDs are functional in the HI-P framework...................................... 61
HI-P+: Coupling kinases to PBDs with phosphosite resolution ............................... 65
Optimization of phosphoprotein expression .............................................................. 68
Targeted assays for in-depth phosphoprotein studies ................................................... 70
Genetic code expansion provides a novel toolkit for studying kinase functions ....... 70
Chapter 4: Conclusion and future directions ............................................................... 74
Summary of genetic code expansion with phospho-amino acids ................................. 74
Applications of co-translational insertion of phospho-amino acids .............................. 79
Future expansion of orthogonal translation systems ..................................................... 83
Chapter 5: Methods ........................................................................................................ 88
Cell growth and general techniques .............................................................................. 88
v

Construction of OTSs and strains.................................................................................. 89
C321XpT & BL21XpT strain creation ........................................................................... 89
C321XpS Strain construction ...................................................................................... 90
Construction of pThrOTS vectors .............................................................................. 91
Construction of pSerOTS vectors .............................................................................. 92
Construction of pTyrOTS and related vectors........................................................... 92
Growth characterization............................................................................................ 93
Protein production and purification............................................................................... 93
Analytical gel and immunoblotting............................................................................ 93
MS-READ reporter purification ................................................................................ 94
CHK2, Thr, and pThr library purification ................................................................ 94
Protein digestion and mass spectrometry ...................................................................... 96
MS-READ analysis .................................................................................................... 96
Digestion of intact E. coli for shotgun proteomics .................................................... 97
Phosphothreonine Phosphosite library digestion, enrichment and dephosphorylation
................................................................................................................................... 98
CHK2 and threonine phosphosite library digestion ................................................ 100
Threonine phosphosite library fractionation........................................................... 100
CHK2 phospho-enrichment ..................................................................................... 100
Data acquisition and analysis ................................................................................. 100
vi

pThr metabolite mass spectrometry......................................................................... 102
High-throughput Interactome of Phosphoproteins ...................................................... 102
FACS ........................................................................................................................ 102
Next generation sequencing analysis ...................................................................... 104
Kinase screening ......................................................................................................... 105
In vitro kinase reactions .......................................................................................... 105
References ...................................................................................................................... 106

vii

List of Figures & Tables
Figure 1-1| The 64 codons of the genetic code ................................................................... 3
Figure 1-2| The process of protein translation .................................................................... 4
Figure 1-3| Mechanism of protein phosphorylation............................................................ 7
Figure 1-4| Overview of tRNASer ...................................................................................... 10
Figure 1-5| Codon reassignment enables genetic code expansion .................................... 18
Figure 2-1| Screening pThrOTSs informs optimal design elements ................................. 23
Figure 2-2| pSerOTS impacts E. coli fitness ..................................................................... 25
Figure 2-3| Rank order comparison of pSerRS expression ............................................... 26
Figure 2-4| tRNA copy number variations have minimal impact on pThrOTS
performance ...................................................................................................................... 30
Figure 2-5| tRNA copy number variations alter growth and protein production with
pSerOTSs .......................................................................................................................... 31
Figure 2-6| tRNApSer identity elements inform on mis-aminoacylation profiles .............. 33
Figure 2-7| Hammerhead ribozyme enables inducible tRNA transcription...................... 36
Figure 2-8| tRNA copy number variations alter growth and protein production within a
pSerOTS............................................................................................................................ 38
Figure 2-9| pSer- and pThrOTSs can decode UGA codons .............................................. 41
Figure 2-10| Gene deletions enhance pThr production ..................................................... 45
Figure 2-11| pThrOTS expression displays hallmarks of stringent response activation... 46
Figure 2-12| C321XpS cellular proteomes vary with OTS expression ............................... 49
Figure 2-13| pSerOTSλ displays markers of the stringent response ................................. 50
Figure 2-14| pTyrOTS is capable of incorporating pTyr at UAG codons ........................ 53
Figure 2-15| Tyr auxotrophy reveals potential targets for enhanced pTyr import ............ 54
viii

Figure 3-1| High-throughput Interactome of Phosphoproteins (HI-P) overview.............. 57
Figure 3-2| 14-3-3β HI-P recapitulates known motifs and functions ............................... 58
Figure 3-3| Evolutionarily conserved PBDs functionally enrich with HI-P ..................... 60
Figure 3-4| The SHP2 SH2 domain lacks specificity with C321EpY ................................. 62
Figure 3-5| Kinase profiling of CHK2 reveals known motifs and substrates ................... 64
Figure 3-6| HI-P+ links phospho-binding activity to a kinase of interest ......................... 67
Figure 3-7| Production of phosphosite libraries varies by expression conditions............. 69
Figure 3-8| Genetic code expansion provides novel insights into CHK2 activity ............ 72
Figure 3-9| CHK2 Analysis of CHK2 variant phosphorylation status ............................. 73
Figure 4-1| Co-translational insertion of phosphoamino acids enables recombinant
phosphoprotein production ............................................................................................... 78
Figure 4-2| Summary of systems-level studies enabled by genetic code expansion ........ 82

ix

Chapter 1: Introduction
Protein translation
The central dogma of molecular biology states that DNA is transcribed into RNA
and then translated into proteins. In this manner, these three codes are the basis for all life
on Earth. DNA and RNA consist of a 4-base nucleic acid code that results in a final
complexity of 20 core amino acids in cells. RNA is read as 3-nucleotide codons to address
this increase in complexity, giving rise to a potential 64 possible combinations (Fig 1-1).
The way the cell accomplishes the conversion of nucleic acids to amino acids is through
protein translation. Protein translation is a multi-step process involving the concerted
action of RNA and protein across the cell (Fig 1-2). Specifically, the process starts when
an aminoacyl-tRNA synthetase (aaRS) binds to a transfer RNA (tRNA) and aminoacylates
it with a cognate amino acid. The elongation factor (EF) binds the aminoacylated tRNA to
facilitate its movement and entry into the ribosome. The ribosome, a complex structure of
ribosomal RNA and proteins, catalyzes amide bonds between amino acids to produce
proteins. This occurs when the aminoacyl-tRNA enters the aminoacyl (A) site of the
ribosome, checking for the proper base pairing between the three base tRNA anticodon and
the three base mRNA codon. If the tRNA effectively binds the correct sequence, it enters
into the peptidyl (P) site of the ribosome. Within the P site, the ribosome enzymatically
attaches the amino acid to the growing peptide chain. The tRNA then enters the exit (E)
site, where it can dissociate from the ribosomal complex. This process proceeds forward
until the ribosome encounters a stop codon, UAG, UGA, or UAA. When this occurs in E.
coli, one of two main release factors (RF1 or RF2) enter the ribosome, causing termination
of the protein sequence and dissociation of the ribosomal complex. Each RF has unique
properties; for instance, RF1 facilitates release at UAG and UAA codons but requires the
1

help of RF3 to release from the ribosomal complex [1]. Conversely, RF2 terminates
translation at UGA and UAA codons but does not require RF3 to facilitate its release.
Through this complex process, the cell can make up the majority of protein effectors
essential for biological functions.
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Figure 1-1| The 64 codons of the genetic code
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Figure 1-2| The process of protein translation
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Most estimates for the human genome approximate the complexity around 20,000
genes [2], but the array of proteins making up the proteome is far more incredible. The vast
majority of this complexity is due to alternative splicing and the addition of reversible, sitespecific post-translational modifications (PTMs). The most ubiquitous reversible PTM is
protein phosphorylation, with estimates reaching ~230,000 unique sites across the human
proteome [3]. Mechanisms of phosphorylation-dependent regulation occur when a protein
kinase attaches a phosphate molecule from ATP to the hydroxyl group of serine (Ser),
threonine (Thr), or tyrosine (Tyr) to make phosphoserine (pSer), phosphothreonine (pThr),
or phosphotyrosine (pTyr) within a protein (Fig. 1-3). This mechanism can be rapidly
reversed by phosphatases, enzymes that remove the phosphate group by hydrolysis.
Although protein kinases only encompass ~500 genes [4], they account for most
characterized PTMs across the proteome. Advances in proteomics have increased our
ability to identify phosphorylation sites (phosphosites), yielding an expansive map of the
human phosphoproteome. However, the identification of these sites has outpaced our
ability to connect them to underlying interactions. Connecting phosphorylation sites to
function across the proteome has been challenging due to a lack of comprehensive
information regarding the identity of upstream activating kinases, the inherently dynamic
nature of kinase and phosphatase effectors, and the modulation of PPIs by non-catalytic
phospho-binding proteins. Protein phosphorylation also occurs on other amino acids, such
as histidine (His), aspartic acid (Asp), and cysteine (Cys), but these modifications are
generally confined to prokaryotes and may only exist as a tiny fraction within eukaryotes
[5-7]. The phosphorylation of proteins can facilitate many different cellular functions,

5

including changes in localization, complexation, and activity. For instance, many protein
kinases require site-specific phosphorylation of their activation loop to facilitate
conformational changes to an active state [8, 9]. Likewise, many protein-protein
interactions (PPIs) are dependent on phosphorylation. This is increasingly recognized with
phospho-binding proteins, such as the 14-3-3 proteins, and their role in sequestering
phospho-proteins [10-12]. These regulatory complexities underscore the need for
technological advances that facilitate the rapid investigation of phosphorylation-dependent
signaling on a systems-wide scale.

6

Figure 1-3| Mechanism of protein phosphorylation

7

Suppressor tRNAs
Orthogonal translation systems (OTSs) in which an orthogonal aminoacyl-tRNA
synthetase (aaRS) and tRNA pair have been repurposed for co-translational insertion of a
modified amino acid is a combination of several previously validated technologies. The
first discovery that enabled future OTS work was the suppressor tRNA in 1965 [13, 14].
Suppressor tRNAs occur naturally when a mutation in the anticodon causes the tRNA to
recognize and decode a stop codon, leading to nonsense suppression (Fig 1-4). This finding
provided the first evidence that a stop codon could be repurposed to incorporate an amino
acid. Since then, several other naturally occurring E. coli suppressor tRNAs have been
identified [15, 16]. Since the initial discovery, we have come to understand that only a
particular subset of tRNAs can function as suppressors.
The ability of a tRNA to become a suppressor depends on how the identity elements
of the tRNA are recognized by the aaRS, if the aaRS will still maintain aminoacylation
efficiency and fidelity, and whether or not mutations in the anticodon are stable enough to
persist in a population. This has been well studied with Ser suppression of UAG codons by
the SupD tRNA [15]. It has since been repurposed for several applications in genetic code
expansion [17]. The serine aaRS is particularly amenable to interacting with Ser suppressor
tRNAs because it lacks an anticodon binding domain. In many other synthetases, such as
the threonyl-tRNA synthetase, the anticodon binding domain binds to the anticodon
recognizing either ACA, ACC, ACG, or ACU. If the anticodon sequence is incorrect, i.e.,
does not start with the sequence AC, it will not bind the tRNA. Conversely, the seryl-tRNA
synthetase relies upon an enhanced variable loop (Fig 1-4) to determine tRNA identity.

8

This subtle difference allows for tRNASer to contain a broader range of anticodon identities,
as evidenced by Ser decoding six different codons (Fig 1-1).
The variable nature of the anticodon is also due, in part, to the ‘wobble’ of tRNAs
in decoding mRNA sequences [18]. During protein translation, the first two nucleotides of
the tRNA anticodon interact with the corresponding codon of the mRNA sequence in the
ribosome; as long as the first two codons pair correctly, the third codon does not have to
pair perfectly. This third codon facilitated ‘wobble’ in the tRNA allows for decoding of
mRNA codons that are not an exact match. Although still an area of study, it appears that
post-transcriptional modifications to the tRNA play a key role in facilitating this wobble,
or lack thereof. For instance, it is known that specific tRNAs, such as E. coli tRNAPhe, have
adenosine at position 37 that becomes post-transcriptionally modified to 2-methylthio-N6
isopentenyl adenosine [19]. This modification stabilizes the tRNA anticodon within the
ribosome and decreases frameshifting, thereby enhancing fidelity. Insights such as these
have been instrumental in improving the fidelity and function of tRNAs in OTSs.

9

Figure 1-4| Overview of tRNASer
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Incorporation of non-standard amino acids
The other significant advancement that led to the development of OTSs was
recognizing that non-standard amino acids (nsAAs) could be incorporated into proteins
within a cell. The first instance of this was by Cowie and Cohen in 1957, in which it was
discovered that selenomethionine, a methionine (Met) derivative, could be incorporated at
Met codons in a Met auxotrophic E. coli strain [20]. Following this initial discovery, there
was a dramatic increase in the number of nsAAs that were found to replace canonical amino
acids [21]. One major limitation of this work was an inability to retain native protein
function. For instance, one of the earliest experiments demonstrated that although it was
possible to replace His with 2-methylhistidine in a His auxotrophic strain, isolated alkaline
phosphatase was inactive [22]. Other studies performed in a similar manner were able to
retain some functionality in alkaline phosphatase through misincorporation of low levels
of fluorotyrosine [23]. In general, only a tiny portion of incorporated nsAAs could retain
protein function and those that did generally had a deleterious effect on growth and fitness.
In order to mitigate these effects, experiments on the incorporation of nsAAs occurred in
organisms that could tolerate mistranslation mediated proteome stress, such as E. coli, B.
subtilis, or bacteriophages [21, 24].
The first evidence that tRNAs could be made to incorporate different amino acids
selectively occurred in 1962 when it was shown that cysteinyl-tRNACys could be
chemically converted to alanyl-tRNACys and still function as the same donor tRNA during
ribosomal protein synthesis in vitro [25]. Traditional methods involving aminoacylation of
near cognate amino acids relied upon mutant or evolutionarily divergent aaRSs; however,
more recent work has relied upon the flexizyme system developed by the Suga group [26].
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The flexizyme system makes use of a ribozyme (flexizyme) that catalyzes tRNA
aminoacylation through recognition of the 3’-CCA of tRNAs and transfer of a chemically
activated amino acid [26-28]. Since its development, it has been applied to numerous
standard and nsAAs in various contexts [29, 30].

The advent of orthogonal translation systems
Most organisms utilize the same genetic code; that is, 64 possible codons read in a
relatively identical manner across kingdoms. However, several observations have given
rise to the idea of genetic code expansion in organisms. Repurposing the genetic code
occurs every day in human cells, where mitochondrial tRNAMet must decode both AUG
and AUA codons; however, cytosolic tRNAMet only decodes AUG, with AUA reserved for
tRNAIle [31]. The more well-known instance of an altered genetic code across all kingdoms
of life is the selenocysteine (Sec) system, in which Ser-tRNASec is first phosphorylated by
phosphoseryl-tRNA kinase to generate pSer-tRNASec that is then converted to Sec-tRNASec
by Sec synthase [32]. The aminoacylated tRNASec only decodes UGA stop codons
containing mRNA structural elements that recruit the Sec-specific elongation factor. The
highly regulated complex of mRNA and EFs ensures that translational insertion of Sec only
occurs at a specific subset of UGA-containing codons. In light of the complex regulatory
mechanisms associated with Sec, it stands to reason that it plays an essential role in
physiology across prokaryotes and eukaryotes. Current work indicates that Sec is used in
place of catalytic Cys residues for redox reactions, as Sec results in higher enzyme
efficiencies [33]. Although Sec has particular regulatory elements required for its insertion,
the 22nd amino acid, pyrrolysine (Pyl), appears to be more promiscuous. Having only been
12

found in some methanogenic microorganisms, it is believed that the electrophilic imine
bond of Pyl is necessary for the methyl transferase activity of some enzymes [34, 35].
Pyrrolysyl-aminoacyl tRNA synthetase aminoacylates Pyl directly onto tRNAPyl for
incorporation at UAG codons, independent of any complex regulatory elements [36].
Although the incorporation mechanism is unclear, it appears that many of these
methanogens have fewer UAG stop codons throughout their genome when compared to
methanogenic archaea. In this sense, nature has performed the first genome-wide recoding
to enable readthrough of UAG as a sense codon.
The Schultz group created the first OTSs to use UAG nonsense suppression and
nsAAs [37-39]. It was previously established that tRNATyr could be easily converted to a
suppressor tRNA by modifying the anticodon to UAG, thus enabling stop codon
suppression [40]. The Schultz group built on this by finding an evolutionarily divergent
organism, in this case, the archaebacterium Methanococcus jannaschii, that had evolved
an orthogonal Tyr tRNA and aaRS pair that would have minimal cross-reactivity with
native E. coli machinery [39]. The tRNATyr of M. jannaschii has a discriminator base, i.e.,
an identity element required for correct aminoacylation, in the acceptor stem of G:C, while
E. coli tRNATyr has a C:G in the same position. This minor difference is a significant
identity element for TyrRS that varies between M. jannaschii and E. coli. The other benefit
to using M. jannaschii TyrRS is that it lacks an editing domain [41], meaning that
aminoacylation of a non-cognate amino acid would not be removed by the aaRS. Using
site-directed mutagenesis, the Schultz group was able to evolve the active site of the M.
jannaschii TyrRS to allow for incorporation of the nsAA O-methyl-L-tyrosine at UAG
codons in E. coli.
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The incorporation of nsAAs into E. coli proteins were a significant step forward for
the field, but it was not until this was expanded to pSer that OTSs could be used for probing
phosphorylation-dependent biological questions. The pSerOTS was the first OTS capable
of incorporating a nsAA to produce a recombinant post-translationally modified protein. It
relied upon a phosphoseryl-tRNA synthetase (pSerRS) from Methanococcus maripluidus
to aminoacylate pSer onto a modified UAG tRNACys suppressor from M. jannaschii [42].
As the tRNACys was not the native substrate for pSerRS, it required an additional mutation
of C20U to enhance aminoacylation activity. Additionally, E. coli elongation factor Tu
(EF-Tu) was evolved to accommodate the negative charge associated with pSer to generate
EF-pSer. To provide a robust pool of pSer substrate, the E. coli phosphoserine phosphatase,
serB, was deleted from the genome. It is known that pSer is produced endogenously in E.
coli during the serine biosynthesis pathway, in which serC converts 3-phosphooxypyruvate
to pSer, which is converted to Ser via serB [43]. This evolutionarily conserved pathway
has been essential for expanding the genetic code to pSer in E. coli and human cells alike
[17, 42, 44, 45]. Unfortunately, the first pSerOTS suffered from low fidelity and poor
efficiency due to problems with substrate specificity and incomplete orthogonality. The
first solution to these problems came through modification of the OTS, in which pSerRS,
tRNApSer, EF-pSer were evolved for enhanced fidelity [46]. These enhanced variants
(pSerRS9 and EF-pSer21) became the basis for further OTS developments in our lab [17].
OTSs have since been developed to facilitate the incorporation of phosphotyrosine
(pTyr) [47-49] and phosphothreonine (pThr) [50], greatly expanding our understanding of
phosphoprotein function. Iterations of pTyrOTSs utilize M. jannaschii TyrRS and tRNATyr
pair but have proven particularly challenging to develop high fidelity OTSs for. The earliest
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reported instance used a five-phosphatase knockout strain to facilitate pTyr import into the
cell but resulted in low yields of pTyr containing proteins [47]. Later systems overcame
the issue by using a Lys-pTyr dipeptide to enhance pTyr import [49]. By using the dipeptide
ABC transporter periplasmic binding protein (DppA), it is possible to import an
impermeable amino acid across the periplasmic space of E. coli through linkage to a
standard amino acid [51, 52]. Interestingly, the pTyrRS used in these experiments was not
evolved for pTyr, but rather the non-hydrolyzable analogue p-carboxymethyl-lphenylalanine (CMF) [53]. Although pTyr mimetics cross the E. coli periplasmic space
without modification, they are often poor substitutes for pTyr [54, 55]. Other groups have
tried to circumvent these problems by chemically protecting the phospho-moiety of pTyr
until incorporation into a protein of interest [48]. The major flaw in this design is that it
requires an extracted protein to be treated to low pH conditions (~2) for up to 36 hours to
remove the protecting group.
Despite the success of pSer, and to a lesser extent pTyr, in the production of
recombinant phosphoproteins in E. coli, only one group, to date, has made progress towards
a functional pThrOTS. The Chin group first reported on a pThrOTS in 2017 [50], with little
to no follow-up from the community-at-large. The pThrOTS was enabled by two
advancements: 1) an evolved pSerRS to accommodate pThr and 2) use of the Salmonella
typhimurium enzyme pduX to catalyze the conversion Thr to pThr. Although the pThrOTS
was developed several years ago, it has yet to be deployed for functional studies of protein
phosphorylation.

15

Recoded Organisms
Although organisms with intact Pyl systems make use of the UAG codon as a sense
codon, they have a built-in redundancy of an in-frame UGA or UAA stop codon to
accommodate read-through [36]. However, it was believed that UAG read-through of
essential genes in E. coli was causing an OTS-specific growth defect. To address this
challenge, a genomically recoded E. coli strain (C321.ΔA) was developed in which all 321
instances of the TAG codon were recoded to TAA (Fig 1-5) [56]. These mutations enabled
deletion of RF1 (ΔA), thereby decreasing competition for nsAA incorporation at UAG
codons. Recoding efforts have further progressed, with the most ambitious efforts centering
around a 57 codon E. coli, missing the UAG stop codon, as well as two codons for Arg,
Leu, and Ser [57]. Although the 57-codon organism was never fully completed, the Chin
group produced a 61-codon organism (Syn61) via large-scale DNA synthesis techniques
[58]. The Syn61 organism is missing the UAG stop codon, as well as the Ser codons TCG
and TCA. An evolved version of Syn61 was later demonstrated to utilize multiple OTSs
simultaneously, allowing for high-fidelity site-specific incorporation of three nsAAs
simultaneously [59]. Future recoding efforts are underway for more complex organisms
such as yeast [60-63] but still require substantial effort for completion.
Despite these advancements, there is still a lack of knowledge surrounding the
physiological impact of OTS deployment in E. coli that has hindered performance. To
expand our understanding of the contribution of host processes to OTS function, we
systematically optimized the architecture and expression of pThrOTS and pSerOTS
components while monitoring the impact on cellular viability. Using previously
characterized aaRS, tRNA, and EF components, we developed rationally designed and
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optimized OTSs capable of facilitating high levels of phosphoamino acid incorporation.
Together with several strain innovations that maximized the production of
phosphoproteins, we were able to perform system-wide screens phospho-mediated proteinprotein interactions (PPIs). Using these technologies, we characterized a novel mechanism
of activation for checkpoint kinase 2 (CHK2). Utilizing a novel tRNAAla suppressor, we
demonstrated that phospho-ablative mutations may obfuscate complex phosphorylationdependent interactions for CHK2 activation. Coupling our ability to produce active kinases
with our platform to identify phosphorylation-dependent PPIs, we profiled the overlap
between CHK2 substrate phosphorylation and 14-3-3β phosphorylation-dependent
interactions. Overall, our work demonstrates the utility of application-driven phosphoamino acid-based OTS development and highlights how genetic code expansion to the
human phosphoproteome allows for the facile characterization of multi-level kinase and
phospho-binding domain-dependent PPIs.

17

Figure 1-5| Codon reassignment enables genetic code expansion
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Chapter 2: Optimizing the incorporation of phospho-amino acids in E.
coli
Refining orthogonal translation component expression
Establishing a robust pThrOTS
To determine baseline functionality of the initial pThrOTS components, we first
incorporated them into our previously developed OTS framework (pSerOTSλ) consisting
of the pThr aminoacyl-tRNA synthetase (pThrRS) and pSer elongation factor 1 (EF-pSer1)
under control of a high-level constitutive TRC promoter. [17, 42, 50]. EF-pSer1, along
with a further optimized variant (EF-pSer21), were evolved from a bacterial elongation
factor (EF-Tu) to facilitate efficient delivery of negatively charged phospho-aminoacyltRNA to the ribosome [42, 46]. To create a stable intracellular pool of pThr substrate, the
pThrOTS system relies upon the bacterial enzyme pduX to catalyze the ATP-dependent
conversion of free L-threonine to pThr [50, 64]. Our initial pThrOTS framework placed
pduX under the control of the arabinose inducible promoter (pBAD). The expression of
tRNA was controlled by a constitutive lpp promoter and was further modified to be
insulated by surrounding terminators. We conducted our preliminary pThrOTS
optimizations in a C321.ΔA strain with a deletion in serC (C321ΔserC), the enzyme which
converts metabolic precursors to pSer during Ser biosynthesis [65]. We reasoned that
limiting the intracellular levels of pSer would decrease competition for pThr at the pThrRS
active site. Using this framework, we systematically modified OTS and vector components
to identify their impact on the fitness of the host cell.
We used growth rate as a proxy for cellular fitness and OTS toxicity to pre-filter
deleterious OTS variants from our initial pool of 41 OTSs (Table 1), selecting 12 for further
analysis. Growth rate data identified antibiotic selection and promoter strength as
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significant determinants of OTS toxicity (Fig 2-1A). To assess pThr incorporation
facilitated by the remaining OTS variants, we utilized our Mass Spectrometry Reporter for
Exact Amino acid Decoding (MS-READ) reporter protein [66]. The reporter is a 6x His
tagged, TAG-containing elastin-like polypeptide, green fluorescent protein fusion that can
be used to monitor relative pThr-protein expression by immunoblot and quantify amino
acid incorporation at UAG codons by MS. To qualitatively assess OTS function, we
expressed the reporter protein with each OTS variant and analyzed pThr-protein production
by Phos-Tag-SDS-PAGE (which separates proteins based on phosphorylation status) with
western blot for the 6x His tag. Samples from the same reporter proteins were then analyzed
by MS to quantitatively assess pThr incorporation relative to other amino acids
incorporated at the UAG codon. Combining these data with cellular fitness metrics, we
observed that growth rate reduction, caused by increased pThrRS promoter strength, was
inversely correlated with reporter expression and pThr incorporation (Fig 2-1A). Because
promoter activity emerged as an essential mediator of pThr incorporation, we wanted to
assess the impact of promoter strength variation on pduX expression and pThr production.
We constructed pduX expression vectors with diverse transcriptional promoters and
measured the levels of pduX protein and pThr metabolites by LC-MS/MS (Fig 2-1B). We
observed that the TRC promoter (Fig 2-1B, P4) consistently facilitated the highest pduX
expression and pThr production (Fig 2-1B). While transcriptional promoter strength was
identified as a determinant of OTS toxicity and performance, additional elements of OTS
architecture appeared to impact host cellular fitness. These observations were collectively
used to inform design principles for our optimized pThrOTS variant. The optimized variant
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(pThrOTSZeus) placed pduX in a polycistronic operon with pThrRS and EF-pSer21 under
transcriptional control of the TRC promoter (Fig 2-1C).
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Table 2-1| Table of pThrOTSs tested
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Figure 2-1| Screening pThrOTSs informs optimal design elements
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Expanding the stability of pSerOTS components
Our lab had previously developed pSerOTSλ [17], in which pSerRS9 and EFpSer21 are constitutively expressed under a TRC* promoter, with four copies of a tRNApSer
cassette. Although functional, pSerOTSλ has been observed to cause growth defects and
strain instability in some contexts. We started our initial experiments in a C321.ΔA strain
with a deletion in serB, the phosphatase responsible for converting pSer to Ser [43], to
make our experimental pSer strain C321XpS. In these cells, the addition of pSerOTSλ
caused a stark decrease in growth rate compared to cells lacking the OTS. We also found
that cell size, an indicator of stress in E. coli, was increased ~50% in cells containing
pSerOTSλ (Fig 2-2A). Transformations of pSerOTSλ into traditional BL21 protein
expression cells were unsuccessful, most likely due to the toxicity associated with UAG
read-through.
To identify how component expression was altered with pSerOTS, we focused on
expressing individual OTS components to narrow down key features of function. We
focused first on the expression of pSerRS, comparing its expression under the control of
the modified TRC promoter (TRC*), which provided constitutive, high-level expression
against that of the low-level constitutive glnS* promoter [67]. Compared to E. coli lacking
an OTS (WT), cells expressing pSerRS under control of glnS* showed a slight growth
defect, while cells expressing pSerRS under control of TRC* displayed a significant
decrease in growth (Fig 2-2B).
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Figure 2-2| pSerOTS impacts E. coli fitness
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Figure 2-3| Rank order comparison of pSerRS expression
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To better understand the implications of OTS expression on the host cell, we
performed shotgun proteomics on C321XpS cells expressing different pSerOTSs. Namely,
we compared the relative pSerRS expression in cells transformed with pSerOTSλ against
pSerOTS variants using the glnS* promoter with different copy number origins. Using the
proteomic data, we constructed rank-ordered lists based on the relative abundance of
individual E. coli and OTS proteins. pSerRS and native E. coli aaRSs are plotted for each
experimental condition in Fig 2-3, with native E. coli aaRSs marked for relative
comparison. While most E. coli aaRSs ranked in the 300-400 range, pSerRS from
pSerOTSλ was one of the cell's top 10 most abundant proteins. The high level of pSerRS
expression provides context for the slow growth and toxicity often seen with its expression.
Presumably, pSerRS is altering the global landscape of amino acid availability through
alterations in the Ser biosynthesis pathway, but a more in-depth mass spectrometry-based
analysis of amino acid pools would be required for validation. Alterations to intracellular
amino acid and tRNA pools have been previously demonstrated to decrease aaRS
selectivity resulting in mistranslation events in E. coli and S. cerevisiae [68, 69]. Using this
information, we designed our second-generation pSerOTS base plasmid, pSerOTSc, with
a ColE1 origin, pSerRS:EF-pSer operon under the control of glnS*, and a single copy of
tRNApSer under the E. coli promoter/terminator pair proK [70]. This ColE1-based OTS was
used as the basis for comparison of future pSerOTS experiments, noted as C321EpS.
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Exploration of tRNA usage in orthogonal translation systems
tRNA copy number stability in pThrOTS design
Our experiments regarding pThrOTS identified the role of pThrRS and EF-pSer
expression in meditating cellular toxicity and phosphoprotein production, thus allowing us
to produce pThrOTSZeus. To simplify the expanded diversity of these initial experiments,
we opted for using a single copy of tRNApThr. To enhance transcription of the single tRNA,
we altered the lpp promoter and rrnC terminator system from pSerOTSλ to the native E.
coli proK promoter/terminator pair [70]. To evaluate the role of tRNA copy number in
pThrOTSZeus, we produced vectors containing 1x, 2x, 3x, and 4x copies of tRNApThr. As
we had previously seen high rates of tRNA recombination with pSerOTSλ, presumably
due to the four tRNA cassettes being identical, we sought to maintain high transcription of
the tRNA without producing identical genetic elements. Further borrowing from native E.
coli machinery, we used the valU tRNA linker, a genetic sequence that enhances
maturation and folding of the tRNAs through RNase P meditated processing [71]. The
addition of a valU linker, in theory, should minimize the rates of recombination by
providing divergent genetic sequences around the tRNA while maintaining a high copy
number. Attempts to increase copy number using an additional linker, valX, and tRNA
resulted in multiple tRNA mutations. Instead, individual copies of the tRNA or 2x tRNA
cassettes were used to make additional 3x and 4x variants (Fig 2-4A).
To assess how tRNA copy number affected phosphoprotein production, we cotransformed each variant with our MS-READ reporter and performed a qualitative analysis
by Phos-tag gel and immunoblot in a modified BL21 strain. We found that generally, the
level of phosphoprotein remained consistent across samples but that the increase in copy
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number led to more non-phosphorylated protein being produced (Fig 2-4B). Based on these
results, we determined that the 3x and 4x variants provided limited utility for quality
phosphoprotein production. For a more in-depth analysis of how tRNA copy number may
be affecting phosphoprotein production, we performed shotgun proteomics on our MSREAD reporter protein, looking at the fidelity of incorporation at UAG codons (Fig 2-4C).
We were unable to identify significant differences in either phospho- or nonphosphoprotein protein production. As the 1x tRNA variant should be more genetically
stable, we opted to use it as our basis for future experiments.
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Figure 2-4| tRNA copy number variations have minimal impact on pThrOTS
performance
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Figure 2-5| tRNA copy number variations alter growth and protein production with
pSerOTSs
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pSerOTS tRNA variations
One of the essential aspects of OTS design depends upon choosing the appropriate
tRNA copy number. With pSerOTSc as a base, we created OTS variants with increasing
tRNA copy numbers (Fig 2-5A). We transformed these OTS variants into both C321XpS
and BL21XpS. In both cells, we observed a decrease in growth rate as the tRNA copy
number was increased, with more than two copies of the tRNA being non-viable in BL21.
When the OTS origin was switched to a lower copy p15a vector, cells were better able to
handle increases in tRNA copy number (Fig 2-5B).
Variants of pSerOTSc with 1x, 2x, 4x, or 6x tRNApSer were co-transformed into
C321XpS cells with the MS-READ reporter protein. We found a copy number-dependent
increase in the relative incorporation rates of Gly and Thr relative to pSer (Fig 2-6). With
lower tRNA copy numbers, the rate of mis-aminoacylation stays low, but as the amount of
tRNApSer rises, the misincorporation of Gly and Thr increases in a non-linear fashion. In
addition to Gly and Thr, we also found appreciable levels of Ser incorporation at UAG
codons. Mapping the E. coli SerRS recognition elements to tRNApSer identified a low
degree of overlap with tRNASer. Although it is impossible to rule out dephosphorylation as
a confounding factor, the degree of overlap in identity elements provides evidence to the
idea that the native SerRS is likely not interacting with the orthogonal tRNApSer (Fig 2-6)
[72]. The tRNA-dependent increase in the relative ratio of Ser:pSer indicates that Ser may
be mis-aminoacylated onto tRNApSer by pSerRS. Based on these findings, we surmised that
the tRNA-dependent increase in non-pSer containing reporter protein results from tRNA
mis-aminoacylation. These results indicate that balancing the ratio of tRNA to aaRS is
essential for maintaining fidelity in OTS-dependent protein expression.
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Figure 2-6| tRNApSer identity elements inform on mis-aminoacylation profiles
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Inducing tRNA transcription with self-splicing RNA elements
One of the often-unaddressed issues of OTS expression is the role of deacylated
tRNA in meditating cellular toxicity. It is known that when deacylated tRNA enters the Asite of the ribosome, it activates relA, which in turn produces the alarmone (p)ppGpp [7375]. The presence of (p)ppGpp in the cell causes a signal cascade that activates the stringent
response, where amino acid biosynthesis is upregulated, and general translation is downregulated. Although most tRNAs within an OTS are considered ‘orthogonal,’ they would
still be able to activate the stringent response if they enter the A-site of the ribosome. This
issue is further confounded in OTSs by the inducible expression of the aaRS. If the aaRS
is not induced, then the orthogonal tRNA pool will generally remain deacylated until its
expression. As most protein expression protocols require cells to reach the mid-log phase
before induction, there is a significant time gap in which the tRNA is most likely activating
the stringent response, hampering protein expression before it has even begun.
To address this issue, we sought to create an inducible tRNA system that would be
contained to the same polycistronic operon as the aaRS and EF. This would require a
mechanism by which the tRNAs could be cleaved from the RNA transcript for further
processing by RNase P. We found that hammerhead ribozyme could, in theory, satisfy
these requirements. To test this theory, we produced pThrOTS variants in which the
pThrRS:EF-pSer21:pduX operon was now linked to hammerhead ribozyme:tRNApThr (Fig
2-7A), with a second variant containing an additional tRNApThr with a valU linker.
Modified C321 cells were then co-transformation with the MS-READ reporter to assess
phosphoprotein production via Phos-tag gel and immunoblot (Fig 2-7B). As a proof of
concept, we found that cells were capable of producing recombinant phosphoproteins using
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the inducible ribozyme system; however, the overall yield was considerably lower than
what we find with pThrOTSZeus. This indicates that although the system is functional, more
copies of the tRNA are required to produce appreciable amounts of a phosphoprotein. It
may be possible to incorporate more tRNA linkers, such as valX, ileT, or alaT, to produce
a large operon consisting of more tRNAs.
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Figure 2-7| Hammerhead ribozyme enables inducible tRNA transcription
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Changes in tRNApSer recognition elements enable Ala suppression
It was previously shown that mutations in tRNApSer helped decrease misaminoacylation by native E. coli aminoacyl-tRNA synthetases, facilitating enhanced pSer
incorporation [50]. In an attempt to reduce Gly mis-aminoacylation, we redesigned
tRNApSer from a previously characterized pSerOTS [17] by adding recognition elements
for D-aminoacyl-tRNA deacylase (DTD), an enzyme whose secondary function is to
prevent Gly misincorporation by hydrolyzing mis-glycylated tRNAs (Fig 2-8A) [76].
Using MS-READ, we profiled the fidelity of our modified tRNA and, surprisingly,
discovered that our modified tRNA functioned as an Ala suppressor tRNA (Fig 2-8B). The
serendipitous development of an Ala suppressor tRNA provided a novel mechanism to
program non-phosphorylatable residues in recombinantly expressed proteins genetically.
Further investigation revealed that the major tRNA recognition element for E. coli AlaRS
is G3:U70 [77], a mutation we had made to enhance recognition by DTD. Thus, our
tRNAAla
CUA enables the production of a non-phosphorylatable version for the protein of
interest using the same UAG containing construct.
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Figure 2-8| tRNA copy number variations alter growth and protein production within a
pSerOTS
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Expanding the phosphoamino-acid genetic code to UGA codons
Although UAG codons have traditionally been used for genetic code expansion, it
is not inconceivable that it could be adapted for use at additional stop codons. In order to
expand the genetic code to multiple phosphoamino acids, we sought to create OTSs that
could decode UGA codons and would theoretically be orthogonal to each other to facilitate
the production of dually phosphorylated proteins. Many essential signaling cascades
require the use of multiple phosphoamino acids for activation, for example, ERK1 & 2,
which requires both a pThr and pTyr in the activation loop [78]. To this end, we created a
series of pSer- and pThrOTSs containing tRNAs that would decode at UGA. For pThr, we
opted only to modify the one tRNA in pThrOTSZeus, but as pSerOTSs have been evolved
numerous times, we decided to begin with a larger contingent of pSerOTSs. Modifications
to pSerOTSλ including replacing TRC* for an inducible TRC promoter, replacement of
pSer

pSerRS9 with pSerRS1, and inclusion of tRNA cassette containing 2x tRNAUCA under
control of the lpp promoter. We then co-transformed these vectors with the MS-READ
reporter protein to ascertain function. Using Phos-tag gels and immunoblot for qualitative
pSer

analysis, we found that only pSerRS1 was able to aminoacylate tRNAUCA , EF-pSer
variants did not alter phosphoprotein yields, and that the constitutive TRC* promoter
enhanced phosphoprotein production (Fig 2-9A). We also found that pThrOTSZeus was able
pThr

to aminoacylate tRNAUCA , but not efficiently (Fig 2-9B). Due to the low protein yield
produced by UGA pThrOTSZeus, we sought to characterize its decoding efficiency using
our MS-READ reporter protein analyzed by MS/MS. We validated that pThrOTSZeus
was
UGA
successfully incorporating pThr at UGA codons (Fig 2-9C), albeit at low levels (Fig 2-9B).
Our results indicate that it is possible to incorporate phospho-amino acids at UGA codons
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but with a tradeoff in efficiency. Future directions with whole-genome recoding may ease
the burden by removing UGA codons and deleting RF2.
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Figure 2-9| pSer- and pThrOTSs can decode UGA codons
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Genetic modifications to E. coli enhance phospho-protein production
Recombinant pThr protein production is enhanced in phosphatase deletion strains
In order to identify host contributions to OTS performance, we use targeted
deletions to screen 16 candidate genes that could increase pThr protein production (Fig 210A). This approach showed that individual deletions of serC, ycdX and pphA enhanced
phosphoprotein production. The impact of these candidates on steady-state pThr-protein
levels was subsequently assessed both individually and combinatorically in BL21 and a
modified C321 strain (C321.ΔA.exp). Strains with individual deletions for pphA or ycdX
produced comparable levels of phosphoprotein reporter, while serC deletion strains
showed significant increases in non-phosphoprotein production (Fig 2-10B&C). The triple
knockout (TKO), experimental pThr strains (BL21XpT and C321XpT) further improved the
ratio of non-phosphorylated to phosphorylated protein reporter, mainly in C321XpT. We
next used MS-READ to quantify amino acid incorporation at UAG codons for each strain
background and constructed a heat map using precursor ion intensity as a proxy for amino
acid incorporation frequency (Fig 2-10D&E). Consistent with our Phos-Tag SDS-PAGE
gels, the combinatorial knockouts facilitated the highest pThr-protein production. For
future experiments, we designated the C321XpT and BL21XpT strains containing the
episomal pThrOTSZeus vector as C321EpT and BL21EpT. These results highlight how host
pathways can be altered to improve OTS performance.
In order to better understand the contributions of OTS architecture to cellular
toxicity, we analyzed the proteome of C321ΔserC cells with and without a pThrOTS (Fig
2-1A, O2) and identified 463 host proteins with significantly altered expression. Protein
network and GO enrichment analyses identified a cluster of metabolic sub-networks
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involved in amino acid biosynthesis and catabolic processes (Fig 2-11A). The emergence
of these networks suggests constitutive high-level OTS expression imparts a metabolic
burden that could initiate host stress responses and ultimately diminish pThr protein
expression. As noted earlier, this may, in part, be due to activation of the stringent response,
either by low-affinity aminoacylation by pThrRS or excessive amounts of unaminoacylated
tRNApThr. This was of particular concern as the stringent response decreases intracellular
Thr levels [79], decreasing available substrates for pThr production via pduX. To
investigate this mechanism, we knocked out the primary stringent response effector, relA,
in C321EpT and BL21EpT strains generating C321EpTΔrelA and BL21EpTΔrelA. Using
qualitative immunoblot analysis, we found no discernable difference in the ratio of
phosphorylated to non-phosphorylated protein between the strains, suggesting that the
stringent response was unlikely to significantly impact phosphoprotein production (Fig 211B). In order to expand the scope and diversity of human phosphoprotein production in
our new strains, we gathered data from the PhosphoSitePlus database and constructed a
codon-optimized phosphosite library DNA array corresponding to 57,536 unique pThr
sites and flanking 15 amino acid sequences (resulting in 31 amino acids for each
phosphosite) [80, 81]. Due to the absence of well-characterized Thr amber suppressor
tRNAs, a duplicate library was synthesized by substitution of the central TAG codon for
ACC to enable expression of a non-phosphorylated, Thr-containing proteome array.
As an initial experiment, we began by expressing the entire pThr phosphosite
library in each of the four strains. We found that in regards to overall protein expression,
there was minimal difference between genetic backgrounds (Fig 2-11C). However, many
of our high-throughput experiments require a complex array of phosphosite expression in
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vivo; in other words, we require a healthy cell population to perform most of our
phosphosite-related experiments. To test this functionality, we used a bimolecular
fluorescence complementation assay in which a protein-binding domain (PBD) is fused to
the C-terminal half of mCherry to facilitate interactions with a phosphosite fused to the Nterminal half of mCherry for reconstitution of the fluorescent protein. We utilize this
technique to produce High-throughput Interactomes of Phosphoproteins (HI-P) for
systems-wide phospho-interactomics. As a measure of quality control in our assay, we
wanted to understand how the relA KO background may be affecting the production of our
phosphosite library. To do this, we made use of 14-3-3β, a PBD our lab had extensively
validated with the pSer phosphosite library [80]. We found that only the C321 strains
produced fluorescent cells, i.e., enrichment for phosphosites, but only the C321EpTΔrelA
strain could produce a significant enrichment across multiple rounds (Fig 2-11D). The
evidence indicates a toxicity effect from pThrOTSZeus meditated productive phosphosite
expression that is mitigated in the C321EpTΔrelA strain. Conversely, the BL21 strains never
experience a significant shift in fluorescence across cell populations. Whether this is due
to OTS-mediated toxicity or limitations imposed by competition with the native release
factor requires further investigation.
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Figure 2-10| Gene deletions enhance pThr production
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Figure 2-11| pThrOTS expression displays hallmarks of stringent response activation
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The optimized pSerOTSc is minimally toxic in C321
As seen with pThr, shotgun proteomics provides insights into cellular processes
that may be altered by OTS expression. In order to understand the effects of pSerOTS
components on C321XpS cellular processes, we expressed episomal vectors containing
either the tRNA alone or pSerRS alone (derived from pSerOTSλ). Comparing this dataset
to that of pSerOTSc, and cells devoid of pSerOTS should enable us to understand better
what metabolic processes are altered in a component-specific manner. We created rankordered protein abundance lists and performed statistical analyses to identify significant
changes. The lists of proteins with significantly up-regulated and down-regulated protein
expression compared to the C321XpS control were cross-referenced to identify overlap
between each experimental condition (Fig 2-12A). We found that pSerOTSc had 57 upregulated proteins and 67 down-regulated proteins compared to the C321XpS control, while
pSerOTSλ and the λ aaRS control had 2-3x as many proteins upregulated and
downregulated (Fig 2-12A&B). The fact that pSerOTSλ has dramatically altered the host
proteome highlights the importance of understanding OTS-mediated toxicity.
To better understand OTS-mediated changes to the proteome, we constructed
volcano plots comparing the up- and down-regulated proteins in pSerOTSλ and pSerOTSc.
Points outside the curved boundaries represent significant changes, with those to the right
representing up-regulated proteins and those to the left down-regulated proteins. As we had
previously seen that expression of pSerOTSλ resulted in pSerRS being one of the most
abundant cellular proteins, we theorized that the cell might have an increased translation
demand. In order to test this hypothesis, we examined the expression of ribosomal subunit
proteins (red) as a surrogate for translational demand (Fig 2-12C). We found that C321XpS
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cells expressing pSerOTSλ have a significant increase in the levels of ribosomal proteins
compared to cells containing pSerOTSc (Fig 2-12C). This indicates that pSerRS expression
mediated by pSerOTSλ results in a high translational burden even before expressing a
recombinant phosphoprotein. Further analysis of the proteomics data revealed the upregulation of RNA polymerase subunits and nucleotide biosynthesis, as well as the
downregulation of nucleotide degradation, presumably due to the high-level transcription
facilitated by TRC* and five copies of tRNApSer (Fig 2-13). We also found that the tRNAonly OTS resulted in up-regulation of amino acid biosynthesis, an indicator of stringent
response activation by unaminoacylated tRNA pools (Fig 2-13) [82]. Although pSerOTSλ
produces numerous perturbations to the host proteome, pSerOTSc produced relatively few
changes. Based on this information, we designated pSerOTSc in C321XpS as our episomal
pSer strain (C321EpS) for future work. This data highlights the utility of proteomics in
understanding cellular mediated toxicity in OTS expression and provides a template for
further studies.
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Figure 2-12| C321XpS cellular proteomes vary with OTS expression
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Figure 2-13| pSerOTSλ displays markers of the stringent response
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Incorporation of pTyr is limited by intracellular pTyr pools
Early experiments in the development of pTyrOTSs indicated that pTyr might be
entering the periplasm but experiencing dephosphorylation before entering the cell [47].
Further variations circumvented this through the use of pTyr analogues or pTyr containing
dipeptides to enter the cell [48, 49]. Building on this data, we produced a pTyrOTS
consisting of the Schultz group’s pTyrOTS with the addition of the Söll group’s evolved
elongation factor (EF-pTyr). Using our MS-READ reporter, we initially validated the
experimental pTyrOTS in C321 cells (C321EpY) with the pTyr-Lys dipeptide (Fig 2-14A).
We found that C321EpY was able to incorporate pTyr, but at relatively low levels.
Due to the success of driving intracellular phospho-amino acid production for pSer
and pThr, we attempted to find an enzyme that could produce intracellular pTyr. A
bioinformatic search revealed that phenyl-phosphate synthase, an enzyme isolated from the
soil microbe Thauera aromatica, was shown to readily phosphorylate phenol, the R group,
of Tyr [83, 84]. Although we could express the enzyme complex successfully, we failed to
identify any appreciable incorporation of pTyr with our MS-READ reporter (Fig 2-14B).
As it appeared there was no clear pathway for either producing intracellular pTyr or driving
import of pTyr, we decided to pursue a systems biology approach to understanding pTyr
import. We first generated a Tyr auxotroph by deleting tyrA, a gene responsible for making
an essential Tyr intermediate in E. coli (Fig 2-15A). Cells were then grown in a defined
media lacking Tyr, with or without the addition of pTyr (Fig 2-15B). C321ΔtyrA cells were
grown only in defined media lacking Tyr but containing pTyr. Samples were collected in
triplicate and analyzed via shotgun proteomics. Statistical analyses of relative protein
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abundance revealed C321ΔtyrA cells upregulated aromatic amino acid transporters,
dipeptide transport proteins, and periplasmic phosphatases (Fig 2-15C&D).
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Figure 2-14| pTyrOTS is capable of incorporating pTyr at UAG codons
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Figure 2-15| Tyr auxotrophy reveals potential targets for enhanced pTyr import
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Chapter 3: Applications of the incorporation of phospho-amino acids
Systems biology approaches to understanding protein-protein interactions
Mapping the phospho-interactome of 14-3-3β
Although phosphorylation is generally recognized as a regulatory medium for
kinase-phosphatase-dependent processes, it also facilitates non-enzymatic PPIs via PBDs.
We previously developed the HI-P method for screening individual pSer library members
in parallel with a single PBD (Fig 3-1) [80]. Previously, our work had been limited to pSer,
but the advancement of our pThrOTS technology allowed us, for the first time, to
characterize pThr dependent interactions. Following enrichment of 14-3-3β in our HI-P
system, we sequenced the phosphosites of two replicates from the final pThr population.
We found that 67 phosphosites were shared between the samples, with each sample having
~200 sites. Motif analysis of enriched pThr phosphosites showed that pThr HI-P identified
the canonical 14-3-3 binding motif (-3 Arg, -2 Ser, and +2 Pro; Fig 3-2A) that was also
identified with pSer HI-P [80]. We found a +1 Trp motif unique to pThr, that has been
previously reported in some 14-3-3β studies [85]. To better understand how this may relate
to pSer, we repeated our HI-P experiment with 14-3-3β against the pSer library using the
newly developed C321EpS strain. We were able to identify ~220 pSer-specific 14-3-3β
phosphosites using C321EpS. Motif analysis of enriched pSer phosphosites also identified
the canonical 14-3-3 binding motif (-3 Arg, -2 Ser, and +2 Pro; Fig 3-2A). We then
performed a GO enrichment analysis of biological processes between the pThr and pSer
dataset (Fig 3-2B). There was a low degree of overlap between pSer and pThr biological
processes, with only terms related to cytoskeleton organization being enriched for both

55

sets. Our data indicates that there may be different alternative roles for pThr and pSer in
phospho-binding mechanisms but requires further study.

56

Figure 3-1| High-throughput Interactome of Phosphoproteins (HI-P) overview
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Figure 3-2| 14-3-3β HI-P recapitulates known motifs and functions
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Evolutionarily conserved PBDs interact with human phosphosites
As a further proof-of-concept for our pThr based HI-P system, we decided to test a
forkhead-associated (FHA) phospho-binding domain. FHA domains are known as specific
binders of pThr, which has precluded using the pSer-based HI-P system to characterize its
binding profile. To that end, investigated RAD53, which has one of the most well studied
FHA domains from the yeast S. cerevisiae [86-89]. Deployment of RAD53 in a HI-P
context was highly functional with BL21EpT (Fig 3-3A). Analysis of individual
phosphosite-specific interactions in a 96-well format pre- and post-FACS enrichment
showed a striking shift in the fluorescent population distribution. Unfortunately, analysis
of biological replicates failed to produce a motif, let alone recapitulate a RAD53 motif. In
this instance, we could only identify 111 phosphosites in total, with 71 being shared
between the two sets. The lower count may be due to limitations of yeast binding domains
in a HI-P context or the use of the BL21EpT strain. Although it is not possible to rule out a
loss of specificity due to a mismatch of human phosphosites with a yeast binding domain,
the sequence space covered by our libraries represents a vast array of potential interaction
partners. Functional enrichment for GO biological processes mirror some known processes
as CHK2, the direct human homologue, such as regulation of cycle progression (Fig 3-3B).
Although some of the data was inconclusive, it does provide evidence that it may be
possible to screen evolutionarily divergent PBDs against known human phosphosites in a
high-throughput manner. Future screening with PBDs from other organisms may provide
more insight into the feasibility of such an approach.
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Figure 3-3| Evolutionarily conserved PBDs functionally enrich with HI-P
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The pTyr SH2 PBDs are functional in the HI-P framework
SHP2 is a tyrosine-protein phosphatase containing both an N-terminal and Cterminal Src Homology 2 (SH2) domains associated with cell growth, differentiation, and
oncogenesis [90-94]. The N-terminal SH2 domain of SHP2 has many functions, but the
canonical mechanism allows for cis binding to the SHP2 phosphatase domain, thereby
blocking phosphatase activity [95]. Although such SH2 domains have been well
characterized for their phosphobinding activity, there has never been a large-scale screen
against all the known human pTyr phosphosites. To this end, we sought to characterize the
phosphoproteome-dependent interactions of the N-terminal domain of SHP2 using HI-P
and C321EpY. Using the same methodology for pThr and pSer, we produced a DNA array
containing 38,679 known pTyr phosphosites encoded with a central UAG residue. Using
our pTyrOTS with dipeptide mediated uptake of pTyr and the native M. jannaschii TyrRS
and tRNA pair as a negative control, we were able to test the binding of SH2 domains
across the human phosphoproteome. When utilized in our HI-P system, we found that
SHP2 (and other) SH2 domains display high levels of non-phospho-binding in HI-P (Fig
3-4A). This may be a limitation of C321EpY failing to incorporate high levels of pTyr (Fig
2-14) that could be overcome with future technological advancements. Motif analysis of
the enriched C321EpY samples produced a motif directly opposed to those previously
identified (Fig 3-4B) [96, 97]. However, the enrichment of acidic residues indicates there
be some phospho-memetic binding of the SHP2. This data does not preclude the ability to
use SH2 domains in HI-P but indicates that extensive work is required to adapt both
systems for such use.
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Figure 3-4| The SHP2 SH2 domain lacks specificity with C321EpY

62

Non-phosphorylated phosphosite libraries provide an ideal substrate for kinase screening
The production of active kinases and non-phosphorylated Ser/Thr phosphosite
libraries provides a unique opportunity for the in vitro profiling of kinase substrates across
the human proteome with greater coverage than previous methods [98]. The
serine/threonine kinase, CHK2, is a prime example of a kinase that would provide a wealth
of information by identifying its substrates involved in the modulation of cell cycle
progression and DNA repair pathways [99-103]. By coupling purified Ser and Thr
phosphosite libraries to in vitro kinase reactions and shotgun proteomics, we were able to
profile the activity of both full-length active CHK2 and the CHK2 kinase domain (KD)
containing pThr encoded within the activation loop (Fig 3-5A).
Overall, we identified 230 unique phosphosites when screening with full-length
CHK2, of which 126 phosphosites occurred at least twice across three reactions. We found
evidence for 290 unique phosphosites when screening with the CHK2-KD, with 158
identified at least twice. Most phosphosites were for pSer, corresponding to ~70% for both
full-length and KD variants. Motif analysis of phosphosites identified the canonical CHK2
RxxS/T recognition motif, separation of enriched phosphosites into Ser and Thr sub-pools
revealed unique motif elements that had not been characterized with traditional peptide
arrays [104] (Fig 3-5B). Additional analysis identified pThr specific motifs, specifically, a
+5 Tyr and +7 Cys motif. Our work demonstrates how phosphosite libraries can be
repurposed for the identification of functional kinase substrates in vitro.
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Figure 3-5| Kinase profiling of CHK2 reveals known motifs and substrates
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HI-P+: Coupling kinases to PBDs with phosphosite resolution
A long-standing barrier to establishing mechanisms of phospho-regulation has been
the need for a high-throughput method to connect kinase activity to phosphorylationdependent PPIs while maintaining phosphosite resolution. To address this challenge, we
developed a modified HI-P framework that identifies kinase-specific substrates interacting
with phospho-binding domains across the phosphoproteome. Modification of the HI-P
platform included utilization of the non-phosphorylated Thr-phosphosite library as the
kinase substrate, leaving the TAG codon free for genetically encoded pThr to activate a
kinase of interest (CHK2) (Fig 3-6A). To streamline our approach, we modified
pThrOTSZeus to reduce the metabolic burden with a low copy ClodF13 origin vector [70]
that constitutively expresses a kinase of interest (in this instance, CHK2). This novel
reconfiguration is termed HI-P+ for HI-P “plus” a kinase of interest. Using HI-P+, we coexpressed activated CHK2-KD with the Thr-phosphosite substrate library paired with 143-3 β. HI-P+ enabled a coupled screen where activated CHK2 would phosphorylate
substrates which would, in turn, be identified through binding by 14-3-3β (Fig 3-6A). This
integrated approach to activate CHK2 and drive pThr site-specific PPIs identified 409
human phosphosites that were both CHK2 and 14-3-3β substrates. The high number of
substrates may be over-represented due to the absence of human phosphatases, limiting the
occurrence of low-affinity CHK2 substrates. Comparative motif analysis showed that HIP identified CHK2/14-3-3β substrates with signature amino acids for both proteins (Fig 36B). Interestingly a -3 Arg is preferred by both CHK2 and 14-3-3β (Fig 3-6B), yet a -1
His was preferred in only CHK2 Thr substrates. HI-P+ demonstrated that the -1 His pThr
motif was recognized by 14-3-3β and highlighted how coupling an active kinase with a
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direct PPI readout could uncover kinase-specific PPI network criteria. To add functional
insight to our multi-level, kinase-phospho-binding domain PPI network approach, we
performed a GO enrichment analysis for biological processes on each unique dataset
generated throughout this study (Fig 3-6C). Our analysis revealed a high degree of overlap
for GO-terms related to the cytoskeleton and cellular organization and processes involved
in gene regulation [105]. Overall, our pThrOTS enabled a unique combination of kinase
profiling to establish multi-level phosphoregulatory PPI networks.

HI-P+ adds

unprecedented depth by directly linking kinases and phospho-binding proteins to single
phosphosite PPIs across the human proteome.
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Figure 3-6| HI-P+ links phospho-binding activity to a kinase of interest
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Optimization of phosphoprotein expression
Based on previous work [80], we theorized that different growth conditions could
enhance the expression of our pThr phosphosite library, which encompasses ~57k peptides
containing various chemical properties. Using phosho-enrichment strategies coupled to MS
analysis, we profiled library expression at 37°C and 20°C. After initially identifying a
relatively limited number of phosphosites (~3.5k) across expression conditions (Fig 3-7A),
we theorized that pThr containing peptides might have a decreased ionization efficiency
compared to pSer. In order to test this hypothesis, we used an approach involving
enzymatic de-phosphorylation of phosphopeptides following phospho-enrichment [106].
Phosphatase treatment resulted in the identification of an additional 4.5k phosphosites,
supporting the idea that pThr hinders peptide ionization (Fig 3-7A). To characterize
phosphosite expression independent of OTS function, we expressed the analogous nonphosphorylated Thr phosphosite library and identified ~25k unique phosphosite peptides
(Fig 3-7B). These data illustrate the depth of our phosphosite library and highlight critical
technical considerations for recombinant pThr-protein analysis by MS.
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Figure 3-7| Production of phosphosite libraries varies by expression conditions
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Targeted assays for in-depth phosphoprotein studies
Genetic code expansion provides a novel toolkit for studying kinase functions
Phosphorylation by protein kinases is integral to signal transduction pathways and
the regulation of cellular processes in mammalian cells. CHK2 kinase is phosphorylated at
Thr68 by ATM in response to DNA damage, enabling CHK2 dimerization and transphosphorylation of activation loop residues Thr383 and Thr387 [107, 108]. Previous
reports of recombinant CHK2 expression identified that full-length CHK2 undergoes transphosphorylation during protein expression and purification, yielding catalytically active
kinase [109]. Trans-autoactivation at two regulatory pThr sites is difficult to dissect with
traditional mutagenesis because amino acid substitutions that eliminate Thr sites can
interfere with activation loop function. We aimed to use genetically encoded pThr to probe
the precise mechanisms of CHK2 activation using the kinase domain (KD). Directly
encoding pThr can potentially isolate the precise contributions of each pThr site without
altering the primary activation loop sequence. We constructed a series of KD variants to
dissect the contributions of each phosphorylation state to overall kinase activity (Fig 38A). Our initial analysis recapitulated previous observations of hyper-phosphorylation in
full-length CHK2 and autoactivation of the KD. Double alanine substitution at Thr383 and
Thr387 inactivated both the full-length kinase and the KD. Phos-Tag SDS-PAGE gels of
the wildtype KD (Thr383/Thr387) suggested that only a single activation loop Thr was
auto-phosphorylated, and MS analysis localized the phosphorylation site to Thr383 (Fig 39A&C). Direct synthesis of pThr383/Thr387 CHK2 KD appeared to result in
hyperphosphorylation, while a pThr383/Ala387 mutant more closely resembled the
wildtype KD shift (Fig 3-8A, lane four compared to lanes six and seven). We expected the
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insertion of pThr387 into the KD to produce a phosphorylation profile similar to
pThr383/Thr387 KD; however, we only observed a single phosphorylation state (Fig 38A, columns 8&9). MS analysis confirmed that the genetically programmed pThr387 was
the only phosphorylation event within the activation loop (Fig 3-9A&D). Interestingly,
encoding pThr at positions 383 and 387 produced a unique mixture of singly and doubly
phosphorylated KD that was not recapitulated by any other variant. Detection of pThr383
in the activation loop of any CHK2 variant always corresponded with catalytic activity (Fig
3-9B, C&E). These results indicate that pThr383 is the sole residue responsible for CHK2
activation, while conversely, pThr387 serves to inhibit CHK2 activity.
To assess the activity of the KD variants, we performed in vitro phosphorylation
assays using a 23 amino acid peptide of the well-characterized substrate CDC25C [100]
(Fig 3-8A&B). Across all KD variants, only three phosphorylated the CDC25C substrate:
full-length CHK2, wildtype KD, and pThr383 KD. We also observed that while
pThr383/Thr387 was active, pThr383/Ala387 was inactive. Upon further investigation, we
found that insertion of Ala at either position 383 or 387 ablated the KD activity (Fig 3-8C).
However, Ala substitution at Thr225, another well-characterized CHK2 phosphosite [110],
had no impact on KD activity or autophosphorylation. Our data indicate that alanine
substitution at either activation loop position results in kinase inactivation but through a
mechanism more complicated than phosphosite ablation. Collectivity this data shows that
pThr383 is necessary and sufficient to activate CHK2 and implies that Thr383
phosphorylation may be the first step in CHK2 activation.
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Figure 3-8| Genetic code expansion provides novel insights into CHK2 activity
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Figure 3-9| CHK2 Analysis of CHK2 variant phosphorylation status
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Chapter 4: Conclusion and future directions
Summary of genetic code expansion with phospho-amino acids
Since their discovery, a vast array of OTSs have been developed to incorporate
diverse chemistries into recombinant proteins [111, 112]. Although genetic code expansion
has been implemented across many different organisms [113-119], it is generally E. colicentric. Despite the over-representation of E. coli in genetic code expansion, there is a lack
of knowledge on how OTS expression impacts the host proteome. Many OTSs rely upon
traditional protein expression strains, e.g., BL21, to enhance protein yield, opting to purify
away truncated proteins [50]. A significant advancement came with the arrival of the
recoded E. coli C321, enabling the first instance in which RF1 could be deleted. [120]. This
minor change allowed for the installation of nsAAs as the 22nd amino acid at UAG codons,
facilitating a wide array of new functions and activities [17, 120-122].
OTSs have provided unparalleled access to the study of PTM mediated proteinprotein interactions. Many PTMs, such as protein phosphorylation, are reversible and often
transient in their native environments. Protein phosphorylation is the most utilized PTM
across the human proteome, but its labile nature makes it challenging to study [123, 124].
The site-specific incorporation of phospho-amino acids by OTSs has helped to address
some of these challenges. Initial work centered around pSer, due to the serendipitous nature
of archaea natively aminoacylating pSer to tRNACys [42]. Further studies have expanded
OTSs to pThr [50] and pTyr [48, 49, 125], enabling unprecedented access to the
phosphoproteome. By far, the most well-characterized phospho-amino acid based OTS is
the pSerOTS [17, 45, 46, 126], which has since been further modified to include an evolved
aaRS, EF-pSer, and tRNA to enhance incorporation, and use of a non-hydrolyzable
analogue to eliminate phosphatase mediated loss [45, 46]. Although considerable work has
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gone into the co-translational insertion of phospho-amino acids, the field has failed to
optimize OTSs in the context of cellular physiology.
Through systematic investigation of OTS components, we developed pSer-, pThr-,
and pTyrOTS variants with improved efficiency for the co-translational insertion of
phospho-amino acids at UAG codons (Fig 4-1). Systems-level interrogations of
components demonstrated that OTS toxicity was due, in large part, to high-level aaRS
expression. Reductions to plasmid copy number and regulation of component expression
were central to enhancing pSer- and pThrOTS performance by reducing the metabolic
burden on the host cell. Counter-intuitively, high-level expression of pSerRS results in
decreased protein yield, while low-level expression enhances yield. Only in light of the
cell’s response to stimuli is it apparent that high-level expression activates the stringent
response, thereby hampering protein output. Although this limitation was readily addressed
with pSerOTS, pThrOTS designs required the deletion of relA to produce similar results.
Further design considerations include antibiotic resistance genes, which can alter
translational burden and fidelity, highlighting an important but often overlooked,
consideration for OTS design. Kanamycin, for example, interacts with the 30S ribosomal
subunit to promote mistranslation, potentially enhancing non-standard amino acid
incorporation, whereas tetracycline prevents aminoacylated-tRNA from entering the
ribosomal A-site, undermining global translation [127, 128]. As pThr- and pTyrOTS
activity are contingent upon intracellular phospho-amino acid pools for the production of
aminoacylated-tRNA, the balance of tRNA and the amino acid substrate is integral to
maintaining translational fidelity and regulation. For pThr, this is addressed through the
expression of the Salmonella enterica enzyme, pduX [64], but is more limited for pTyr.
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Dipeptide-mediated incorporation of pTyr, although functional, is currently technically
challenging to produce and cost-prohibitive. Our work on Tyr auxotrophy provides the first
insights into potential methods for increasing intracellular pTyr pools but requires further
validation.
Although OTS components are generally believed to be orthogonal, our work
shows that the incorporation of near-cognate amino acids is mediated by tRNA recognition
elements conserved between prokaryotes and archaea. Despite the limited sequence space
of tRNAs, minor substitutions can completely alter aminoacylation profiles and activity.
We found that nucleotide substitutions to decrease mis-aminoacylation by Gly [76, 77]
serendipitously provided a tRNAAla suppressor, providing a method for incorporating
phospho-ablative mutations in the same UAG containing constructs. The discovery of a
novel suppressor tRNA underscores the importance of tRNA identity elements in OTS
construction, representing a tRNA that has sequentially been evolved from Cys to pSer and
finally to Ala with less than six nucleotide changes. Altering the anticodon, a shared
recognition motif for aaRS editing domains, decreased phosphoprotein production in our
hands. However, this may be mediated by RF1 competition but would require a strain with
UGA recoded strain to verify.
Our findings, as a whole, demonstrate the issues surrounding incomplete
orthogonality in OTS function. The field has traditionally avoided identifying limiting
factors, providing a conformation bias in successive OTS production. This work highlights
that better OTS design practices can decrease cellular toxicity, improve protein production,
and enable more high-throughput studies of nsAAs. As a whole, our systematic approach
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to OTS optimization generated improved pSer- and pThrOTSs, and notably contributed
valuable insight into the rational design of OTSs by monitoring host cellular viability.
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Figure 4-1| Co-translational insertion of phosphoamino acids enables recombinant
phosphoprotein production
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Applications of co-translational insertion of phospho-amino acids
The promise of genetic code expansion to phospho-amino acids has been towards
the advent of robust biological studies. To this end, we sought to characterize, for the first
time, the effects of separate phosphosites on the activation loop of a kinase. CHK2, a
Ser/Thr kinase involved cell cycle regulation, has been shown to have dual phosphorylation
of Thr383 and Thr387 during activation by ATM [107, 108]. Our C321EpT strain allowed,
for the first time, identification of pThr383 within the CHK2 activation loop as the essential
residue regulating kinase activity. The trans-phosphorylation activity of recombinantly
expressed CHK2 made it previously impossible to dissect the independent contributions of
specific phosphosites to CHK2 activity in vitro. Genetically encoded pThr is the only way
to dissect such mechanisms. Together with our pThrOTS and the discovery of a novel Ala
suppressor tRNA, we were able to evaluate the phoshpho-regulatory mechanisms of CHK2
in unprecedented detail. These advances demonstrate the general utility of our approach
towards the characterization of individual kinase regulatory events, and ultimately, the
expansion of our global understanding of phospho-regulatory mechanisms.
Building on these mechanisms, we sought to characterize the pThr-specific FHA
binding of CHK2 and the S. cerevisiae homologue RAD53. Unfortunately, we were unable
to recapitulate the phospho-binding activity of CHK2’s FHA domain using HI-P. Utilizing
the same HI-P framework (Fig 4-2B), we demonstrated how phospho-binding domain
function could be maintained across evolutionarily divergent species with RAD53.
Although motif analysis was inconclusive, functional enrichment for GO biological
processes matched CHK2 biology [99-103]. Complications may be due to substrate motif
elements being slightly altered during evolution. Validation of RAD53 interacting
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substrates via AP-MS would provide clarity to the experiment. Initial work with RAD53
used a BL21EpT strain, which, well functional with RAD53, failed to recapitulate results
with 14-3-3β. The development of C321EpTΔrelA allowed us to characterize, for the first
time, the interactome of 14-3-3β pThr sites. Utilizing our C321EpS strain, we characterized
the overlap of 14-3-3β binding between pSer and pThr. Our approach demonstrated the
presence of unique motif elements and altered GO biological process. These enrichments
detail how Ser and Thr may have differentially regulated activity with 14-3-3β and could
be comparatively expanded to other Ser/Thr PBDs.
Using non-phosphorylated versions of our phosphosite libraries, we can rapidly
profile the activity and specificity of Ser/Thr kinases (Fig 4-2A). Leveraging this approach,
we identified the phosphosite substrates for full-length CHK2 and CHK2 pThr383-KD,
allowing us to identify motif elements overlapping with canonical 14-3-3β binding sites.
Until now, the determination of pSer- and pThr-mediated PPIs has been limited to single
protein-substrate interactions. Hi-P+ provides the first cell-type independent platform to
simultaneously link kinases and phospho-binding proteins to individual phosphosites in a
single experimental approach (Fig 4-2C). Multi-level PPIs identified by HI-P+ pave the
way for constructing more comprehensive protein interaction networks linking kinases,
phosphosites, and phospho-binding domains across the human proteome. HI-P+ has the
potential to expand our understanding of phosphorylation-dependent cellular processes.
Although considerable effort went into developing a C321EpY strain, functional
utilization with HI-P produced mixed results. The N-terminal SH2 domain of SHP2
produced a similar fluorescent shift with a pTyrOTS and TyrOTS in HI-P. When analyzed
in conjunction with the inconsistent motif elements indicated that considerably more work
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is required to make C321EpY viable with HI-P. The results may also be complicated by the
unique nature of SH2 domains in receptor tyrosine kinases. The localization of SH2
domains to the membrane of cells limits the number of proteins they encounter during
biological processes, thus precluding the necessary specificity seen with 14-3-3 proteins.
The high degree of enrichment with a TyrOTS indicates a loss of specificity; whether this
is due to SH2 binding or over-expression in E. coli requires further study.
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Figure 4-2| Summary of systems level studies enabled by genetic code expansion
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Future expansion of orthogonal translation systems
In this work, OTSs have been used to probe specific biological questions and tease
apart systems-wide phosphorylation-specific interactions. Although we now have robust
pSer- and pThrOTSs, significant advances can still be made in both their development and
application. In general, the future of OTS evolution is less in the OTS components and
more in modification of the strains. Despite phospho-amino acids being incorporated as
22nd amino acids, they are still housed on episomal vectors that require constant antibiotic
selection. Future developments could obviate the need for such systems through the stable
integration of pSer- and pThrOTS components, as seen with other nsAAs [129]. Other
modifications include the evolution of the C321 background to revert passenger mutations
derived from recoding. Even though other groups have demonstrated the utility of such
work [130], it has yet to be attempted in an OTS-specific context. The general problem
with installing OTS components and lab-directed evolution is that the fittest population
will probably disrupt the transcription and translation of said components. It is possible to
address this issue by reassigning sense codons to UAG in permissible positions of proteins,
enabling dependence on the OTS [131]. As E. coli does produce some pSer phosphosites
naturally, it may be as simple as mutating known sites throughout the genome in a stably
integrated strain.
This work provides significant advances for pSer- and pThrOTSs, but is still limited
in scope in several regards. The pTyrOTS, featuring a functional aaRS and tRNA pair, is
still hampered by phosphatases and low intracellular levels of pTyr. Target candidates
identified during Tyr auxotrophy experiments provide a putative list of potential genes to
enhance pTyr import. In addition to the limitations of pTyr, there are still several other
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non-traditional phospho-amino acids seen throughout nature, including pHis and pAsp, that
would benefit from OTS development. Canonically, non-traditional phospho-amino acids
are central to bacterial two-component signaling pathways [7, 132], but more recent work
has demonstrated that pHis may play a previously unknown role in mammalian signaling
pathways [133-136]. Genetic code expansion to such non-standard phospho-amino acids
may provide new insights into both human and bacterial physiology.
Even though we have only characterized phospho-amino acid-dependent OTSs,
several other PTMs have come under the purview of genetic code expansion. One of the
most well-characterized OTSs is based on the incorporation of acetyl-lysine (AcK) into
recombinant proteins [137-139]. Lysine acetylation mirrors protein phosphorylation, i.e.,
the addition is catalyzed by acetyltransferases, removed by deacetylases, and bound by
bromodomains (BRDs) [140-142]. AcKOTSs utilize the PylRS and tRNAPyl pair, as they
already decode UAG codons and incorporate a modified Lys [137-139]. The first AcKOTS
utilized the Methanosarcina barkeri PylRS and tRNAPyl [138], but other iterations have
featured the Methanosarcina mazei pair [137, 139]. Despite the significant expansion to
AcKOTSs, there have yet to be any high-throughput studies of acetylation-dependent
interactions. Expanding the scope of HI-P to the High-throughput Interactome of AcK (HIK) through the use of BRDs and large-scale DNA array synthesis could provide novel
insights into AcK function. Although the addition of chromodomains, lysine methylation
binding domains, would also prove helpful, it is currently limited by the use of methyllysine protected analogues in OTS variants [143, 144]. The structural similarity of methyllysine and Lys precludes high substrates specificity for a functional aaRS. Beyond the use
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of protecting groups, the only mechanism to address this problem would be the
incorporation of aaRS editing domains.
Generally, tRNA mis-aminoacylation events are corrected through the use of aaRS
editing domains and trans-editing factors [145-147]. The only OTS to utilize an editing
domain relied on transplantation of the PheRS editing domain (to remove Tyr) into an
evolved TyrRS [148]. Naturally occurring trans editing factors, such as AlaXp, ProXp-x,
ProXp-y, and ProXp-z can remove multiple amino acids that have been misacylated onto
tRNAPro independent of an aaRS [149, 150]. The evolution of these editing factors to
current OTSs and phosphoamino-acids could significantly enhance the fidelity of
incorporation. In particular, ProXp-y already removes misacylated Ser and Thr, which
would be an excellent addition to the pSer- and pThrOTS repertoire [150]. Even though
our work to incorporate recognition elements of DTD into tRNApSer resulted in
aminoacylation by AlaRS, and a serendipitous Ala suppressor, it does not preclude the
evolution of DTD to recognize tRNApSer. If the problem is due to the presence of the
G3:U70, then it should be possible to perform site-directed mutagenesis of DTD to
recognize the C3:G70 of tRNApSer. The advent of such editing mechanisms may become
more critical in implementing multiple OTSs in a single organism.
Expanding the phospho-amino acid based OTS repertoire could provide novel
insights into both eukaryotic and prokaryotic signaling. As researchers expand OTSs to
other PTMs, such as tyrosine sulfonation (sTyr) [151, 152] and nitrosylation (nTyr) [153,
154], it will be possible to understand more complex multi-PTM interactions. For instance,
the 14-3-3 proteins are nitrosylated at Tyr residues during oxidative and nitrative stress
[155, 156]. An expansion of this work would make use of encoding nTyr within 14-3-3
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proteins to test for changes in interactions with pSer and pThr using HI-P. Several
additional PTMs have been characterized within 14-3-3 proteins that do not have a clear
function, including multiple phosphorylation sites [157] that may also be worth studying
in a dual PTM dependent HI-P context. Other expansions of the dual PTM interactome
may help identify how disease-relevant PTMs are regulated. A target with a high
therapeutic value is CCR5, a chemokine receptor essential for the uptake of HIV-1 into
cells [158, 159]. The interaction between CCR5 and HIV-1 depends on the sulfonation of
multiple Tyr residues at the N-terminal domain to facilitate entry [160]. However,
phosphorylation of C-terminal Ser residues may play a role in entry into endosomes [161,
162]. Combining the sTyr- and pSerOTSs with modifications necessary for GPCR
expression in E. coli [163] could provide novel insight into the structural and functional
role of PTMs in CCR5 function.
Other limitations to the field include an inability to incorporate multiple phosphoamino acids into a given protein. ERK1 & 2, significant mediators of cell growth and
immune activation, rely upon both pThr and pTyr in the activation loop for proper function
[78]. Our work in expanding pSer- and pThrOTSs to decode at UGA codons provides a
proof-of-principle that it is possible to repurpose an additional stop codon for genetic code
expansion. Based on the experiments described throughout, it is now theoretically possible
to encode pThr at UGA and pTyr at UAG to make selectively phosphorylated versions of
ERK1 & 2, e.g., single pThr, single pTyr, or both phosphosites. This may reveal novel
insights into activation, as seen with CHK2. Expanding incorporation of dual phosphoamino acids would also provide a means to activate every member of the kinome.
Combining this technology with our ability to create non-phosphorylated versions of every

86

known pSer, pThr, and pTyr phosphosite would theoretically allow for the screening of
every kinase substrate in a cell-type independent manner, without the need for mammalian
or insect cell lines.
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Chapter 5: Methods
Cell growth and general techniques
All DNA oligonucleotides were obtained with standard purification and desalting
from Keck Oligonucleotide Resource, Yale University. DNA sequencing services were
obtained through the Keck DNA Sequencing facility, Yale University. Unless otherwise
stated, all cultures were grown at 37°C in LB-Lennox medium (LB, 10 g/L bacto tryptone,
5 g/L sodium chloride, 5 g/L yeast extract). LB agar plates were LB plus 16 g/L bacto agar.
Antibiotics were supplemented for selection, where appropriate (Kanamycin at 50 μg/mL,
Spectinomycin at 50 μg/mL, Tetracycline at 12 μg/mL, and Ampicillin at 100 μg/mL). LyspTyr dipeptide was added to a concentration of 2 mM as needed. E. coli Top10 cells
(Invitrogen, Carlsbad, CA) were used for cloning and plasmid propagation. NEBuilder
HiFi Assembly Mix and restriction enzymes were obtained from New England BioLabs.
Plasmid DNA preparation was carried out with the QIAprep Spin Miniprep Kit (Qiagen).
Pre-cast 4–12% (wt/vol) Bis–Tris SDS–PAGE gels were purchased from Bio-Rad. PhosTag reagent for hand-cast protein gels was purchased from FUJIFILM Wako Chemicals
U.S.A. Corporation.
All plasmids were transformed into recipient strains by electroporation.
Electrocompetent cells were prepared by inoculating 20 mL of LB with 200 μL of saturated
culture and growing at 37°C until reaching an OD600 of 0.4. Cells were harvested by
centrifugation at 8,000 RPM for 2 min. at 4°C. Cells pellets were washed twice with 20
mL ice cold 10% glycerol in deionized water (dH2O). Electrocompetent pellets were resuspended in 100 μL of 10% glycerol in dH2O. 50 ng of plasmid was mixed with 50 μL of
re-suspended electrocompetent cells and transferred to 0.1 cm cuvettes, electroporated
(BioRad GenePulser™, 1.78 kV, 200 Ω, 25 μF), and then immediately resuspended in 600
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μL of LB. Transformed cells were recovered at 37°C for one hour and 100 μL was
subsequently plated on appropriate selective medium.

Construction of OTSs and strains
C321XpT & BL21XpT strain creation
Strains were made using two different methods. The initial individual knockout
strains used in 2-10 were generated used Multiplexed Automatable Genome Engineering
(MAGE) [164]. Briefly, a C321.ΔA strain containing a temperature-inducible lambda red
operon is grown to an OD of 0.4 in 3 mL LB at 34°C. Cells are then set to shake in a 42°C
water bath for 15 minutes and are then pelleted by centrifugation at 13,000 rpm for 30s at
4°C, the supernatant is then removed by pipetting. The cells are then resuspended in 1 mL
of 10% glycerol on ice. The pelleting and resuspension are repeated for a total of 3 times.
Following the final pelleting, cells are resuspended in 50 ul 10% glycerol with 1 μL of 10
μM MAGE oligonucleotide. Cells are then transferred to 0.1 cm cuvettes, electroporated
(BioRad GenePulser™, 1.78 kV, 200 Ω, 25 μF), and then immediately resuspended in 600
μL of LB. Transformed cells were recovered at 34°C for one hour. This process was
repeated a total of three times in one day, with the final set of cells being plated on LB
plates. Knockouts were confirmed using colony PCR. MAGE primers were designed to
produce a frame shift mutation and generate multiple stop codons early in the ORF. MAGE
primers were ordered from IDT with enhanced stability modification (denoted as *). All
primers used in MAGE are listed in Table S1.
All C321.ΔA.exp and BL21 (DE3) based strains were generated by traditional
recombineering methods with a FRT-kanamycin-FRT casette [165]. Primers with
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homology to the gene of interest were amplified from pKD4 [165] to generate a
homologous sequence with an internal FRT-kanamycin-FRT casette. Primers used in this
study were those previously validated for each knockout in the Keio collection [166]. Cells
were grown and transformed by electroporation as stated above, but with ~50 ng of the
PCR product in place of plasmid DNA. Cells were then plated on 50 ng/μl kanamycin LB
plates and grown overnight at 37°C. Individual colonies were then screened for the
presence of the kanamycin-FRT casette or gene of interest. Cells that contained the
kanamycin-FRT casette and were absent the gene of interest were then grown overnight in
5 mL LB containing 50 ng/μl kanamycin in a 15 mL pop-cap (Falcon) tube and set to shake
at 230 RPM and 37°C. The following day cells were then transformed by electroporation,
as mentioned above, using the pCP20 plasmid, containing a temperature sensitive origin
and Flp recombinase. Cells were selected on 100 ng/ul ampicillin LB plates and grown
overnight at 30°C. Individual colonies were then patched on separate plates containing
either 100 ng/ul ampicillin, 50 ng/μl kanamycin, or no antibiotic in LB. Plates were
incubated overnight at 30°C. Individual colonies that were negative for kanamycin
resistance and positive for ampicillin resistance were then streaked on LB plates and
incubated overnight at 42°C. The following day plates were transferred from 42°C to 30°C
for additional growth. When colonies became visible to the eye they were then screened
for the absence of the gene of interest as seen in Fig S3. All primers used for the generation
of knockout cassette and screening for the gene of interest can be found in Table S1.

C321XpS Strain construction
Strain modification using a lambda red based strategy was performed as previously
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described[165]. Briefly, transformants carrying a lambda red plasmid (pKD46) were grown
in 20 mL LB cultures with ampicillin and l-arabinose at 30°C to an OD600 of ≈0.6 and then
made electrocompetent. 10–100 ng of PCR product targeting serB was transfomred into
the prepared cells and recovered in 1 mL of LB for 1 h at 37°C. Following recovery, onehalf was spread onto LB-agar plates with Kanamycin for selection. serB gene deletion was
verified by PCR and selected colonies were purified non-selectively at 37°C remove
pKD46. The KAN deletion cassette was excised from the serB locus using FLP
recombinase (pCP20).

Construction of pThrOTS vectors
The starting pThr tRNA and pThrRS were generated by site-directed mutagenesis
of a pSerOTS [167], gifted from the O'Donoghue lab. The pduX gene, OXB20 promoter,
and proK tRNA casette were produced as separate gene gBlocks from GeneWiz. The EfpSer1 and Ef-pSer21 were amplified from previously reported pSerOTSs [17, 42].
Generally, OTSs were assembled by gibson assembly using NEBuilder HiFi DNA
Assembly master mix (NEB). The pThrOTS backbone was made de novo by a 4 fragment
Gibson assembly. tRNA cassettes were assembled into the pThrOTS backbone by Gibson
assembly to create pThrOTSZeus. The pThrOTSHercules variant was created by 3 fragment
Gibson assembly consisting of the (1) pThrRS/Ef-pSer21/pduX operon, (2) ClodF13
spectinomycin pUltra backbone [49], and (3) CHK2 under control of glnS*. Modifications
to tRNApThr anticodon to UGA were performed using site directed mutagenesis.
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Construction of pSerOTS vectors
Generally, OTS components were amplified from the progenitor OTS, pSerOTSλ
(SepOTSλ, Addgene # 68292). The pSerRS (SepRS9) and EF-pSer (EF-Sep21) were
amplified from pSerOTSλ and placed under the control of the glnS* promoter and
assembled with the kanamycin selection marker and origin of replication from pSerOTSλ
by gibson assembly using NEBuilder HiFi DNA Assembly master mix (NEB). tRNA
expression cassettes (1x-, 2x-, 4x-, and 6x-tRNA) were constructed from a 2x-tRNA
construct under the control of a proK tRNA promoter and terminator and separated by a
valU tRNA linker that was ordered as a DNA fragment from Genewiz. tRNA cassettes
were assembled into the previously assembled pSerRS-EF-pSer backbone by gibson
assembly creating ColE1-based pSerOTSc OTSs. OTS variants with different origins of
replication were created by assembly of Rop amplified from pSerOTSλ into the ColE1based OTSs and p15a variants were created by replacement of ColE1 with p15a origins by
pSer

gibson assembly. A 2x tRNAUCA casette was designed and synthesized by Genewiz and
assembled into vectors via NEBuilder HiFi DNA Assembly master mix (NEB).

Construction of pTyrOTS and related vectors
The starting CMFOTS [53] was gifted from the Schultz lab. Site directed
mutagenesis was performed on episomal housed EF-Tu to reproduce EF-pTyr [47]. The
modified EF was then inserted into a polycistronic operon with CMFRS by gibson
assembly using NEBuilder HiFi DNA Assembly master mix (NEB). Phenylphosphate
synthase subunits were cloned from T. aromatica DNA and inserted into a polycistronic
operon under control of pBAD promoter.
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Growth characterization
Stationary phase pre-cultures were obtained by overnight growth with shaking at
37°C in 5 mL of LB supplemented with antibiotic for plasmid maintenance as appropriate.
Stationary phase cultures were diluted to an OD600 of 0.01 in 250 μL of LB (N=3)
supplemented with appropriate antibiotic and induction reagents. Growth was monitored
on a Biotek Synergy H1 plate reader. OD600 was recorded at 10-minute intervals for 16
hours at 37°C with continuous shaking. Growth rate was determined using growthcurveR
0.3.1 [168] in R 3.5 [169] with RStudio 1.3 [170]. Data was averaged and plotted with
standard deviation.

Protein production and purification
Analytical gel and immunoblotting
100 μM Phos-tag acrylamide (FUJIFILM Wako Chemicals U.S.A. Corporation)
within hand-cast 12% acrylamide gels were used for separation of phosphorylated reporter
proteins. SDS-PAGE gels (4–15% acrylamide, Bio-Rad) and Phos-tag gels were
transferred onto PVDF membranes. All gels were visualized by immunoblot. Anti-6xHis
immunoblots were performed using 1:2,500 diluted rabbit α-6xHis antibody (PA1-983B,
Thermo Fisher Scientific) in 5% w/v milk TBST for 1 h and subsequently washed 3x with
TBST. Secondary antibody incubations used 1:10,000 diluted donkey anti-rabbit HRP
(711-035-152, Jackson ImmunoResearch) in 5% w/v milk in TBST for 1 h and were
subsequently washed 3x in TBST. Protein bands were then visualized using Clarity ECL
substrate (Bio-Rad) and an Amersham Imager 600 (GE Healthcare Life Sciences).
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MS-READ reporter purification
Frozen E. coli cell pellets were thawed on ice. Pellets were lysed by sonication with
a lysis buffer consisting of 50 mM Tris-HCl (pH 7.4, 23°C), 500 mM NaCl, 0.5 mM EGTA,
1mM DTT, 10 % glycerol, 50 mM NaF, and 1 mM Na3O4V. The extract was clarified with
two rounds of centrifugation performed for 20 minutes at 4°C and 14,000 x g. Clarified
lysates were applied to Ni-NTA metal affinity resin and purified according to the
manufacturer's instructions. Wash buffers contained 50 mM Tris pH 7.5, 500 mM NaCl,
0.5 mM EGTA, 1mM DTT, 50 mM NaF, 1 mM Na3VO4 and 20 mM imidazole. Proteins
were eluted with wash buffer containing 250 mM imidazole. Eluted protein was subjected
to 4 rounds of buffer exchange (20mM Tris pH 8.0 and 100mM NaCl) and concentrated
using an Amicon Ultra-0.5 mL 30 kDa molecular weight cutoff spin filter (Millipore Sigma
#UFC503096).

CHK2, Thr, and pThr library purification
1.5L cultures of LB 50 μg/mL Kanamycin, 100 μg/mL Ampicillin were inoculated
to OD 0.1 with overnight culture containing C321 cells expressing pThrOTSZeus (or Ser/Ala
tRNA suppressor plasmids) and the expression plasmid (see supplemental table 1)
containing an MBP-6xHis fusion construct. Cultures were set to shake at 230 RPM, 37°C.
At OD 0.4, 1.5L flasks were induced with IPTG and arabinose, and set back at 230 RPM,
37°C for 4 hours. For the pThr and Thr libraries, an additional round of expression was
similarly inoculated, but grown to and OD of 0.8, induced with IPTG and arabinose, and
set at 230 RPM, 20°C for 20 hours. Cultures were pelleted at 5,000 RPM for 5 minutes,
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transferred to separate 50 mL falcon tubes and frozen at -80°C.
Thawed cell pellets were re-suspended in 30 mL of lysis buffer (50 mM Tris/HCl
pH 7.4, 300 mM NaCl, 1 mM DTT, 1 mg/mL lysozyme, 50 mM NaF, 1 mM NaVO4, Roche
protease inhibitor tablet, 1 μL bezonase), and incubated at room temperature for 20 min,
followed by sonication. The lysates were centrifuged at 45,000g, 45 min, 4°C and the
clarified lysate was transferred to a 15 mL falcon tube, and centrifuged at 45,000g, 25 min,
4°C to remove all remaining insoluble material. The clarified lysate was then purified via
gravity column. Briefly, 6 mLs (3 mL bed volume) of NiNTA agarose beads (Qiagen
#30210) was pre-equilibrated with lysis buffer before applying cell lysate. Resin was then
washed with 100 mL of NiNTA wash buffer (50 mM Tris/HCl pH 7.4, 500 mM NaCl, 500
μM DTT, 50 mM NaF, 1 mM NaVO4, 5% glycerol, 10 mM imidazole) before eluting with
20 mL NiNTA elution buffer (50 mM Tris/HCl pH 7.4, 500 mM NaCl, 1 mM DTT, 50
mM NaF, 1 mM NaVO4, 250 mM imidazole). Eluted protein was then diluted with 20 mL
dilution buffer (20 mM Tris/HCl pH 7.4). 6 mLs (3 mL bed volume) of amylose resin (New
England Biolabs #E8021L) was applied to a new column and equilibrated with 50 mL
amylose wash buffer (20 mM Tris/HCl pH 7.4, 1 mM EDTA, 150 mM NaCl 50 mM NaF,
1 mM NaVO4, 5% glycerol). Diluted protein elution was then applied to amylose column
and washed with 100 mL amylose wash buffer before eluting with 15 mL amylose elution
buffer (20 mM Tris/HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, 10 mM maltose, 50 mM
NaF, 1 mM NaVO4, 5% glycerol). Samples were concentrated down using Amicon ultra15 10kDa cutoff columns (Millipore Sigma #UFC901008). pThr phosphosite libraries were
then frozen at -80°C. CHK2 kinases were dialyzed in SnakeSkin™ (ThermoFisher #68035)
overnight at 4°C in dialysis buffer #1 (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 5 mM
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BME, 10% glycerol), then dialyzed for 4 hours at 4°C in dialysis buffer #2 (50 mM
Tris/HCl pH 7.4, 150 mM NaCl, 5 mM BME, 50% glycerol) before being frozen at -80°C.
Ser/Thr phosphosite libraries were incubated with 20 μl (40 units) PreScission
protease (GE Healthcare Life Sciences) end-over-end overnight at 4°C. The cleaved
samples were then passed through an Amicon molecular weight cutoff to remove the
cleaved MBP and any uncleaved protein. Samples were then concentrated using Amicon
Ultra-0.5 3-kDa (Millipore Sigma #UFC500396) molecular weight cutoff columns and
buffer exchanged with 10 mM Tris, pH 7.4. Eluted protein was subjected to 4 rounds of
buffer exchange (10mM Tris pH 7.4 and 150mM NaCl) and concentrated using an Amicon
30 kDa molecular weight cutoff spin filter (Millipore Sigma # UFC503096).

Protein digestion and mass spectrometry
MS-READ analysis
Affinity purified, buffer exchanged protein was digested and analyzed by mass
spectrometry as described previously with some modifications [17]. The concentration of
protein was determined by UV280 spectroscopy, 5 μg of MS-READ reporter was dissolved
in 12.5 μl solubilization buffer consisting of 10 mM Tris-HCl pH=8.5 (23°C), 10 mM DTT,
1 mM EDTA and 0.5% acid labile surfactant (ALS-101, Protea). Samples were heat
denatured for 15 min at 55°C in a heat block. Alkylation of cysteines was performed with
iodoacetamide (IAA) using a final IAA concentration of 24 mM. The alkylation reaction
proceeded for 30 min at room temperature in the dark. Excess IAA was quenched with 200
mM DTT and the buffer concentration was adjusted using a 1 M Tris-HCl pH 8.5 resulting
in a final Tris-HCl concentration of 150 mM. The reaction was then diluted with water and
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1 M CaCl2 solution to obtain an ALS-101 concentration of 0.045% and 2 mM CaCl2
respectively. Finally, sequencing grade porcine trypsin (Promega) was added to obtain an
enzyme/protein ratio of 1/5.3 and the digest was incubated for 15 h at 37°C without
shaking. The digest was quenched with 20% TFA solution resulting in a sample pH of 2.
Cleavage of the acid cleavable detergent proceeded for 15 min at room temperature.
Digests were frozen at -80°C until further processing. Peptides were desalted on C18
UltraMicroSpin columns (The Nest Group Inc. #SUM SS18V). Columns were initially
conditioned with 400 μL 80% ACN 0.1% TFA followed by 200 uL 0.1% TFA. Samples
were pelleted at 2000g for 1 minute before having lysate applied to columns. Sample was
loaded onto column and washed twice with 400 μL 0.1% TFA before eluting with twice
with 200 μL 80% ACN 0.1% TFA. Peptides were dried in a vacuum centrifuge at room
temperature. Dried peptides were reconstituted and analyzed by LC-MS/MS. Heatmaps
were generated with heatmaply 1.2.1 [171] in R [169] using RStudio [170]

Digestion of E. coli protein extracts for shotgun proteomics
20 mL cultures were inoculated to a starting OD of 0.01 in LB media using an
overnight culture to stationary phase. After reaching mid-log, cells were chilled on ice and
pelleted by centrifugation for 2 min at 8000 rpm. The resulting pellet was frozen at -80°C
for downstream processing. For cell lysis and protein digest, cell pellets were thawed on
ice and 2 μL of cell pellet was transferred to a microcentrifuge tube containing 40 μl of
lysis buffer (10 mM Tris-HCl pH 8.6, 10 mM DTT, 1 mM EDTA, and 0.5 % ALS). Cells
were lysed by vortex for 30 seconds and disulfide bonds were reduced by incubating the
reaction for 30 min. at 55°C. The reaction was briefly quenched on ice and 16 μl of a 60
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mM IAA solution was added. Alkylation of cysteines proceeded for 30 min in the dark.
Excess IAA was quenched with 14 μl of a 25 mM DTT solution and the sample was then
diluted with 330 μl of 183 mM Tris-HCl buffer pH 8.0 supplemented with 2 mM CaCl2.
Proteins were digested overnight using 12 μg sequencing grade trypsin. Following
digestion, the reaction was then quenched with 12.5 μl of a 20 % TFA solution, resulting
in a sample pH ~2. Remaining ALS reagent was cleaved for 15 min at room temperature.
The sample (~30 μg protein) was desalted by reverse phase clean-up using C18 MicroSpin
columns (The Nest Group #SEM SS18V). Briefly, the column was conditioned twice with
400 μL 80% ACN, 0.1% TFA and twice with 400 μL 0.1% TFA by centrifugation. Samples
were pelleted at 2000g for 1 minute before applying lysate to the column. Columns were
then washed twice with 400 μL 0.1% TFA and eluted twice with 200 μL 80% ACN, 0.1%
TFA. The desalted peptides were dried at room temperature in a rotary vacuum centrifuge
and reconstituted in 30 μl 70 % formic acid 0.1 % TFA (3:8 v/v) for peptide quantitation
by UV280. The sample was diluted to a final concentration of 0.2 μg/μl with 5 μl (1 μg)
injected for LC-MS/MS analysis.

Phosphothreonine phosphosite library digestion, enrichment and dephosphorylation
5 mg of purified pThr phosphosite library was digested using S-TrapTM midi
columns (Protifi) per manufacturer’s instructions. Phosphoproteins were then enriched
using Thermo Scientific High-Select™ Fe-NTA Phosphopeptide Enrichment Kit
(#A32992) followed by Thermo Scientific High-Select™ TiO2 Phosphopeptide
Enrichment Kit (#A32993) following manufacturer’s instructions. Samples were split into
separation fractions before being dried in a vacuum centrifuge at room temperature. Pooled
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Fe-NTA and TiO2 flow through was cleaned up and desalted using C18 MicroSpin (The
Nest Group #SEM SS18V) columns as described earlier. One set of phospho-enriched
samples was reconstituted in 2 μl 30 % ACN 0.1 % FA and vortexed for 30s. An additional
10 μL of 3:8 70 % formic acid: 0.1% TFA was added to each sample, and vortexed for 30s
before being spun down. 5 μl was injected for LC-MS/MS analysis.
The remaining dried phospho-enriched samples were resuspended in 50 μL 1x
Protein MetalloPhosphatases (PMP) buffer (NEB) with 10 mM MnCl2. 2,000 units of
lambda phosphatase (NEB #P0753S) and 5 units calf intestinal phosphatase (NEB
#M0525S) were added to each reaction, and incubated at 30°C, 600 rpm, for 1 hour in a
thermo mixer. Samples were cleaned up using 200 μL StageTips similarly to what was
previously described [172]. Tips consisted of 2 1.06 mM diameter punches of Empore C18
(3M #2215) fitted into 200 μL pipette tips. Columns were conditioned with 40 μl methanol
and 30 μl 0.1% TFA. Sample was then acidified with 3 μl 70% FA and vortexed. Sample
was applied to the column and centrifuged at 2800 rpm for 5 minutes. Columns were
washed with 50 μl 0.1% TFA and centrifuged for 3 minutes at 900g. Centrifugation was
repeated with 20 μl 0.1% TFA. StageTips were then transferred to 2 ml protein low bind
tubes (Eppendorf #0030108450) and eluted with 30 μl of 80% ACN 0.1% TFA, centrifuged
at 900g for 1 minute. Elution was repeated with 20 μL of 80% ACN 0.1% TFA, centrifuged
at 900g for 2 minutes. Samples were dried down in a vacuum centrifuge at room
temperature. Samples were then reconstituted in in 2 μl 30 % ACN 0.1 % FA and 10 μL of
3:8 70 % formic acid: 0.1% TFA as described earlier.
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CHK2 and threonine phosphosite library digestion
24 μg of cleaved Thr phosphosite library, and 5 μg CHK2 kinase were digested
using S-TrapTM mini spin columns (Protifi) per manufacturer’s instructions. Following
digestions samples were dried in a vacuum centrifuge at room temperature and frozen at 80°C.

Threonine phosphosite library fractionation
Dried down samples were fractionated using Pierce™ High pH Reversed-Phase
Peptide Fractionation Kit (ThermoFisher #84868) following manufacturer’s instructions.
Samples were then reconstituted in in 2 μl 30 % ACN 0.1 % FA and 10 μL of 3:8 70 %
formic acid: 0.1% TFA as described earlier.

CHK2 phospho-enrichment
Following S-trap digestions, both full length CHK2 and CHK2 KD peptides were
enriched using Thermo Scientific High-Select™ Fe-NTA Phosphopeptide Enrichment Kit
(#A32992) following manufacturer’s instructions. Samples were dried in a vacuum
centrifuge at room temperature and reconstituted in in 2 μl 30 % ACN 0.1 % FA and 10
μL of 3:8 70 % formic acid: 0.1% TFA as described earlier.

Data acquisition and analysis
LC-MS/MS was performed using an ACQUITY UPLC M-Class (Waters) and
Thermo Q Exactive Plus mass spectrometer. The analytical column employed was a 65cm-long, 75-μm-internal-diameter PicoFrit column (New Objective) packed in-house to a
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length of 50 cm with 1.9 μm ReproSil-Pur 120 Å C18-AQ (Dr. Maisch) using methanol as
the packing solvent. Peptide separation was achieved using mixtures of 0.1% formic acid
in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) with a 90-min gradient
0/1, 2/7, 60/24, 65/48, 70/80, 75/80, 80/1, 90/1; (min/%B, linear ramping between steps).
Gradient was performed with a flowrate of 250 nL/min. A single blank injection (5 μl 2%
B) was performed between samples to eliminate peptide carryover on the analytical
column. 100 fmol of trypsin-digested BSA or 100 ng trypsin-digested wildtype K-12
MG1655 E. coli proteins were run periodically between samples as quality control
standards. The mass spectrometer was operated with the following parameters: (MS1)
70,000 resolution, 3e6 AGC target, 300–1,700 m/z scan range; (data dependent-MS2)
17,500 resolution, 1e6 AGC target, top 10 mode, 1.6 m/z isolation window, 27 normalized
collision energy, 90s dynamic exclusion, unassigned and +1 charge exclusion. Data was
searched using Maxquant version 1.6.10.43 with Deamidation (NQ), Oxidation (M), and
Phospho (STY) as variable modifications and Carbamidomethyl (C) or Dithiomethane (C)
as a fixed modification with up to 3 missed cleavages, 5 AA minimum length, and 1% FDR
against targeted libraries. E. coli proteome searches were run against a modified Uniprot
E. coli database (taken on February 9, 2021) containing MS-READ reporter proteins and
OTS components (supplemental data file 2). Phosphosite libraries were run against a
modified FASTA file of the phosphosite library containing a partially digested MBP tag
and 6xHis tag (supplemental data files 3&4). Only phosphosite peptides with a MaxQuant
score greater than 40 were considered. MS-READ search results were quantified using
Skyline version 20.1.0.31. Proteome search results were analyzed with Perseus version
1.6.2.2 using a two-tailed student’s t-test. Ion spectra were taken from searches using
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Mascot Daemon 2.5.1. The MS proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE [173] partner repository.

pThr metabolite mass spectrometry
Experiments were carried out in collaboration with Dr. Xiaojian Shi and Dr.
Hongying Shen at Yale University. LC-MS-based phospho-amino acid profiling
experiment was performed using a Q Exactive plus benchtop orbitrap mass spectrometer
equipped with an Ion Max source and a HESI II probe, coupled to a Vanquish UHPLC
(Thermo Fisher Scientific, San Jose, CA, USA). The LC-MS experiment was following
previously reported methods for mammalian cells [174], with 1 OD equivalent of E. Coli
cells at mid-log phase pelleted for polar metabolite extraction. The data was analyzed using
Xcalibur and GraphPad Prism.

High-throughput Interactome of Phosphoproteins
FACS
20 ml of C321QKO cells containing either no OTS (for Thr libraries) or pThrOTSZeus
were grown to an OD600 of 0.4 and electroporated using the method stated above with either
Thr library or pThr library cloned in the split mCherry vector (see supplemental plasmid
files). The cells were then resuspended in 1.2 mLs of LB and incubated for 1 h at 37°C and
230 RPM in a 15 ml culture tube. Recovered cells were directly inoculated in 20 ml of LB
with 100 ng/μl ampicillin, 50 ng/μl kanamycin and grown overnight at 37°C and 230 RPM.
Cells were plated at 10-4 and 10-5 serial dilutions on LB plates with antibiotic and grown at
37°C overnight. Experiments that proceeded forward required at least 20 colony-forming
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units per 10-5 dilution. The following morning, cultures were diluted to an OD600 of 0.15
in 5 ml of LB containing either 100 ng/μl ampicillin or 100 ng/μl ampicillin and 50 ng/μl
kanamycin grown at 37°C and 230 RPM. The cells were grown until an OD600 between
0.6–0.8 and set on ice. Protein expression was induced using 1 mM IPTG, 0.2% arabinose,
and 100 ng/μL anhydrotetracycline, cells were then grown at 20°C and 230 RPM for 20
hours. 30 μl of cells were resuspended in 3 ml ice cold PBS in a 5 ml polystyrene tube
(Falcon) prior to analysis.
Using a BD FACSAria III, cells were assessed for mCherry-based fluorescence
using a 561-nm laser (Texas Red). Gating was set so that fluorescent enriched cells reached
~200 events/s with a total collection of ~50,000 cells/s. The gating was adjusted for each
phospho-binding domain following successive enrichments to ensure that the most
fluorescent population was isolated each round. Cells were sorted directly into 3 ml LB
without antibiotic, recovered at 37°C and 230 RPM for 3 hours, and then added into 17 mL
LB containing antibiotic and grown overnight at 37°C and 230 RPM (~16 hours). The
following day sorted cell populations were then used as the starting culture for the second
round of protein expression. The procedure for protein expression, preparation for FACS,
and cell sorting was repeated, using the same sorting and gating parameters as the first
round of sorting. Cells were then recovered, regrown, induced and prepared for FACS as
above. Cellular mCherry fluorescence was then observed using the FACSAria III. Enriched
cell populations were visualized using FlowJo 10.6.1. Following the final round of
enrichment overnight cultures were pelleted, transferred to a 2 mL Eppendorf tube, and
frozen at -80°C until it was possible to Miniprep the samples using a Qiagen mini-prep kit
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(#27104). Hi-P experiments were repeated in triplicate during concurrent runs from the
same starting population to minimize transformation bias.

Next generation sequencing analysis
Sample pellets generated from Hi-P were thawed on ice and Miniprepped (Qiagen
#27104) as stated above. 100-200 ng of plasmid DNA was amplified in four reactions using
a

standardized

set

of

OLS

TCTGGGTCGACTGGTGGTACC,

amplification

primers

(forward:
reverse:

CGTACCATGTAGCTTAATCAGCTGTTAAAGCTT) with Q5 polymerase (NEB
#M0491). PCR cycle followed a 98°C denaturation for 30s, 15 cycles of 98°C for 15s,
58°C for 30s, and 72°C for 30s, with a final extension of 72°C for 2 minutes. Samples were
then cleaned and concentrated with a PCR purification kit (Qiagen #28104) to one 50 μL
sample. Samples were then further concentrated with a BluePippin (Sage Science)
selecting for samples between 100-200 bp. Samples were cleaned and concentrated with
a PCR purification kit (Qiagen #28104) to a 40 μL sample. 35 μL of sample at a
concentration of 30-50 ng/μL was then sent to Massachusetts General Hospital Center for
Computational & Integrative Biology DNA Core for CRISPR amplicon next-generation
sequencing.
Sequencing reads were analyzed as reported previously [80]. Briefly, data was first
filtered for quality using Trimmomatic, which applied a sliding window filter of width 2
bp and a Phred score cutoff of 30. If the average quality score over two consecutive bases
fell below 30, the read was trimmed to remove the remaining bases. Quality trimmed read
pairs were then merged using BBMerge with the stringency set to “strict”
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(https://sourceforge.net/projects/bbmap/). Using custom scripts, the merged reads were
then sorted and assigned to the various input libraries based on barcodes added during the
PCR amplification step, libraries are provided in supplemental data files 5&6. The variable
sequence region for each amplicon was then extracted, and for each input library the
abundance of every unique sequence was calculated. Sequences with greater than 10x
enrichment were taken forward for analysis.

Kinase screening
In vitro kinase reactions
All kinase reactions were carried out in 40 mM HEPES pH 7.5, 20 mM MgCl2, 0.1
mg/mL BSA, 50 μM DTT with 200 μM ATP. CHK2 kinase variants tested against
CDC25C substrate were carried out by mixing 300 ng of purified kinase with 3 μg CHKtide
in a 15 μL reaction. Initial time point (0 hours) was taken before addition of ATP to
reaction. Following addition of ATP, reactions were incubated at 30°C for 1 hour shaking
at 600 RPM. Reactions were quenched by mixing equal amounts of 2x Laemmli buffer and
reaction before freezing at -80°C. 6 μL of quenched reaction was then run on a 15 lane,
12% acrylamide, 100 μM Phos-Tag SDS-PAGE immunoblotted with α-6xHis as described
earlier. CHK2 kinase profiling was carried out by mixing 250 ng purified kinase with 3.3
μg cleaved Ser library and 1.7 μg cleaved Thr library in a 40 μL reaction incubated at 30°C
for 4 hours shaking at 600 RPM. After 4 hours reactions were frozen at -80°C before being
digested using S-trap mini columns as described earlier.
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